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Opioids have become a major public health concern in recent years with non-medical use 
of both prescription opioids and heroin on the rise. There have been increases in opioid related 
overdoses, accidental deaths, treatment admissions, and sales associated with the increased illicit 
use of opioids. The following capstone project uses the three paper model to explore some of the 
issues associated with this rising epidemic including prescription opioid policies enacted in 
recent years, the populations these policies impact, and potential effects they may have on drug 
use behavior, as well as additional factors that potentially influence opioid user behavior. Paper 
one explores prescription opioid policy and reviews the literature evaluating these policies. Paper 
two focuses on the non-medical prescription opioid using population and explores how the 
demographic and drug use characteristics of the population differ across time, specifically the 
past decade. Finally, paper three examines heroin use in subgroups of prescription opioid users, 
with the main focus on non-medical OxyContin users compared to other non-medical 
prescription opioid users across the past decade. 
 
Keywords: Prescription opioids, heroin, opioid policy, prescription drug monitoring programs, 
abuse-deterrent formulations, illicit drug use 
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CHAPTER I: OVERVIEW 
 
 Opioids have become a major public health concern in recent years. These substances 
include drugs such as morphine, oxycodone, and heroin.1–3 Opioids bind to opioid receptors and 
act on the central nervous system to relieve pain by reducing the intensity of pain signals to the 
brain.1–3 They are typically used and prescribed in medical settings for the relief of pain. 
Additional effects of opioids may include euphoria, sedation, respiratory depression, and nausea, 
among others.2  
Over the past few decades, non-medical use of both prescription opioids and heroin has 
been on the rise in the U.S.4–6 Parallel to this have been increases in opioid related overdose, 
accidental death, treatment admissions, and prescription opioid sales.7–10 Additionally, several 
policies and programs have been developed and implemented to address the growing problem, 
including prescription drug monitoring programs and abuse-deterrent formulations of 
prescription opioids.11–16 These programs have been shown to alter drug use behavior among the 
prescription opioid using population.17–22  
The following capstone project uses the three paper model to explore some of these 
policies in detail, the populations they impact, and potential effects they may have on drug use 
behavior, as well as additional factors that potentially influence opioid user behavior. 
In the first paper, I explore two types of policies that target access to and the abuse 
potential of prescription opioids: a) prescription drug monitoring programs and b) abuse-
deterrent formulations. In this paper, I explore the characteristics of these intervention efforts, 
research that has been conducted to evaluate them, and make recommendations for future 
evaluation research. The aim of the study is to provide a background of what research has been 
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conducted to examine how these policies have impacted the non-medical prescription opioid 
using population and areas where further research may prove useful. 
The second paper focuses on the non-medical prescription opioid using population. Here, 
I explore how the demographic and drug use characteristics of the population differ across time, 
specifically in the past decade. The aim of this study is to investigate how the non-medical 
prescription opioid using population has changed across demographic and drug use 
characteristics given the substantial increase in prescription opioid policy. The goal is to make 
inferences about the source of these changes and what additional research may help elucidate the 
issue. 
Finally, in paper three, I examine a subgroup of prescription opioid users, non-medical 
OxyContin users, and compare them to other non-medical prescription opioid users. I investigate 
heroin use in this population and how it has differed over the same time period used in the 
second paper, comparing the differences over time. The aim in this study is to determine if the 
changes in heroin use over time in the OxyContin using population are more pronounced at any 
certain point in time and if those differences appear to be larger when compared to the other 
groups. Additionally, the paper aims to describe the demographic and drug use characteristics of 
the OxyContin using population.  
Further justification for each of the papers can be found in the introduction section of 
each. In addition to the three papers, a final chapter discusses the three papers and capstone as a 
whole in terms of public health and policy implications and future directions for research. 
Finally, references, tables, figures, and appendices for all papers are included in a single 
respective section for each, as indicated in the table of contents; these sections are not organized 
by paper in this document. 
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CHAPTER II: PAPER 1 
 




 The U.S. has been facing a growing prescription opioid epidemic in recent decades. 
Estimates from the Substance Abuse and Mental Health Services Administration (SAMHSA)* 
show that in 2013 there were approximately 4.5 million current non-medical prescription pain 
reliever (NMPR) users, which represented 1.7% of the U.S. population.23 Additionally, between 
1999 and 2008, sales of prescription drugs and related overdose death rates quadrupled.24 During 
this time, treatment admissions for prescription drugs grew by nearly 500%, the majority of 
which were for opioid prescription drugs.24 
 Several studies indicate that prescription opioids may function as “gateway” drugs to 
heroin use.25–27 The most commonly abused prescription drugs are opioids, such as hydrocodone 
(Vicodin) and oxycodone (OxyContin).1 Given the similar euphoric and other effects that heroin 
and prescription opioids share, users may turn to heroin when faced with reduced access and 
rising costs of prescription opioids.28  
 NMPR use frequently precedes heroin initiation; one study found that four out of five 
recent heroin initiates between 2002 and 2011 reported having used NMPRs before heroin.29 In 
the same study, only 1% of recent NMPR initiates reported having ever used heroin.29 Another 
study found that early NMPR use in childhood was a significant predictor of heroin initiation in 
                                                          
* See APPENDIX A for full acronym guide 
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young adulthood.30 A qualitative study conducted in Philadelphia and San Francisco found that 
the most commonly reported reasons for transitioning from prescription opioids to heroin were 
cost and ease-of-access to supply after becoming dependent on prescription opioids.26 Another 
study found an association between past year NMPR use and past year heroin use, but did not 
include consideration of each group’s NMPR or heroin use history.31 One study of NMPR users 
found that those at greatest risk of recent heroin initiation between 2002 and 2011 lived in 
metropolitan areas (84.6%), identified as non-Hispanic white (74.0%), and had household 
incomes less than $50,000 per year (56.5%).29 
 Many efforts have been made to curb the increased access to and non-medical use of 
prescription drugs, including development of prescription drug monitoring programs by many 
states and development of abuse-deterring formulations by pharmaceutical companies.11–16 Some 
of these interventions, especially the introduction of abuse-deterring formulations of highly 
abused prescription opioids, have been successful in reducing prescription opioid misuse and 
overdose rates.17–22 However, there are potential externalities that may occur when these large 
scale policies are implemented that were not considered during development of the policies. 
 Studies evaluating the impact of prescription opioid misuse policies on drug use behavior 
are essential in order to improve future approaches. However, it is important to first identify 
what research has already been conducted in order to expand on the existing literature and to 
identify areas where there is need for further understanding. This article focuses on two major 
types of policies that have been implemented in recent years across the U.S. to reduce access to 
and misuse of prescription opioids: a) development of prescription monitoring programs; and b) 
development of abuse-deterrent formulations of prescription opioids. An overview of each policy 
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is provided, along with previous research evaluating the impact of these policies, and finally 
recommendations for future research. 
 
PRESCRIPTION DRUG MONITORING PROGRAMS 
 Prescription drug monitoring programs (PDMPs) have been implemented across the U.S. 
at the state-level and are designed to allow health care providers and others to prevent doctor 
shopping, diversion and drug misuse by providing information on individuals’ prescription 
histories.32,33  The Harold Rogers Prescription Drug Monitoring Program and the National All 
Schedule Prescription Electronic Reporting Act of 2005 (NASPER) were designed to facilitate 
the development of PDMPs by state governments and the number of PDMPs has since increased 
significantly.28,33–35  
 
Characteristics of PDMPs 
 To date, 49 states have some form of an operational PDMP in place, with Missouri being 
the only state without an operational PDMP.33 The characteristics of PDMPs can vary 
significantly from state to state. For instance, not all prescription drugs are monitored by states in 
the same way. The U.S. Drug Enforcement Agency (DEA) categorizes drugs into schedules 
ranging from I to V.11 Schedule I drugs are illegal and defined as “drugs with no currently 
accepted medical use and a high potential for abuse”.36 Schedules II through V are drugs that can 
be prescribed legally in the U.S.11 Drugs are categorized into one of these schedules based on 
their potential for abuse, with schedule I substances having the greatest potential and schedule V 
the least.36 All state PDMPs monitor schedule II through IV substances, with thirty six also 
monitoring schedule V substances.33 
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 The administering agency also varies across state PDMPs.37 The most common 
administering agencies are boards of pharmacy and departments of health, which do so in 20 and 
13 states, respectively.37 Other administering agencies include professional licensing (6 states), 
law enforcement (7 states) and substance abuse agencies (3 states).37 
 States also vary in which types of agencies and individuals have access to the information 
within their respective PDMP. Most states provide access to their PDMP information for health 
care practitioners and pharmacists, as these are the gate keepers to prescription drug access for 
the general population.37 Some states, however, also allow agencies such as law enforcement, 
licensing and regulatory boards, Medicaid programs, research organizations, and medical 
examiners to access their PDMP data.37 The purpose of allowing law enforcement access is so 
they can use the information for criminal investigations of either patients or practitioners 
engaging in illegal or suspicious activity. Similarly, giving licensing and regulatory boards and 
Medicaid programs access to the data allows them to monitor and investigate health care 
practitioners who prescribe drugs monitored by the PDMP. Research organizations can use the 
information to investigate prescription drug trends and research other important topics associated 
with PDMPs, while state medical examiners can use the information to help in investigation of 
cause of death in suspicious cases. Involving additional agencies helps to broaden the scope of 
access to PDMP data and may increase the effectiveness and utility of PDMP programs. 
However, this benefit must be weighted and balanced with the protection and security of patient 
privacy and records. 
Another important characteristic of PDMPs is the frequency of data collection. The 
frequency at which data are reported and entered into the PDMP database can range from daily 
to monthly.37 Daily frequencies are ideal as they allow practitioners and others using the systems 
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to obtain up-to-date information on their patients and thus are likely the most effective in 
preventing illegal and harmful activities and behavior like doctor shopping. Monthly reporting, 
on the other hand, may result in a time gap in obtaining patient prescription behavior during 
which individuals may be able to circumvent the system. 
An important factor in regard to promotion of PDMP effectiveness is prescriber and 
dispenser mandates for registration/enrollment with their state’s PDMP and use of PDMP data 
when appropriate. Mandating registration and use promotes increased participation and in turn 
reduces opportunity for abuse of the system by both practitioners and patients. To date, 25 states 
have legislation in place that mandates registration by health care practitioners prescribing 
monitored drugs and/or dispensers with their PDMP.38 Twenty eight states have mandates 
requiring queries into PDMPs by prescribers and dispensers when monitored substances are 
being provided to patients.38 
A relatively new outcome of PDMPs is interstate information sharing.37 Given that 
PDMPs are operated on a state-by-state basis, doctor shopping and other illegal activities may be 
more easily conducted in border regions between states. Having data sharing agreements can aid 
in preventing cross-border activity. As of March 2016, thirty fives state PDMP programs were 
engaged in some form of interstate data sharing, while nine were in the process of implementing 
plans for interstate data sharing.37  
 
Evaluation and Impact of PDMPs 
 There have been several evaluations of PDMPs showing an association with improved 
outcomes related to prescription drug use.28,34,39–45 Studies have found that PDMPs were related 
to slowed growth in the supply of prescription drugs to consumers; decreased prescription-drug-
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related treatment rates, prescription rates and poison center calls; and reduced prescription drug-
related costs, such as medical claims and workers’ compensation.28,34,39–45  
 A study conducted in 2006 by Simeone Associates, Inc., a public policy consulting firm, 
evaluated the impact PDMPs have had on supply of prescription drugs and misuse.28 The study 
used the Automation of Reports and Consolidated Orders System (ARCOS) to estimate the 
supply of schedule II controlled substances. They also used the Treatment Episode Data Set 
(TEDS) as a proxy to estimate prescription drug misuse.28 Additionally, they factored in program 
characteristics in the analysis, for example the “proactivity” of the PDMP. Proactive was defined 
in the study as a state having a PDMP in place that generates unsolicited reports when they are 
determined to be warranted.28 The authors found that states with PDMPs in place had reductions 
in the per capita supply of prescription pain relievers and stimulants over time, after 
implementation of the PDMP.28 They also found that admissions rates to substance abuse 
treatment facilities for each type of drug were positively associated with supply.28 The analysis 
also indicated that states with “proactive” PDMPs, as defined by the authors, may be reducing 
the supply of prescription drugs, specifically prescription pain relievers and stimulants, at a 
greater rate than those states that have “non-proactive” PDMPs.28 
The findings of the study are useful as they indicate that PDMPs do have an effect on 
supply of prescription drugs and, in turn, treatment admission rates for prescription pain relievers 
and stimulants. However, admissions represent only a fraction of the prescription drug abusing 
population and thus may not give an accurate representation of what is occurring in the entire 
population. Other data sets, such as the National Survey on Drug Use and Health (NSDUH), 
which measures substance use behavior in the United States annually, could be used in similar 
analyses to estimate the effect of supply of prescription drugs on drug use behavior.46 
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In 2006, an article published in Health Services Research investigated geographic 
variation in opioid use in various patient populations nationally.40 They used an outpatient 
prescription claims database to determine the prevalence of opioid prescriptions among the 
sample.40 They aggregated data at both the state and county level.40 The authors investigated a 
range of explanatory factors, one of which was presence of a prescription drug monitoring 
program.40 In the study, one model showed a negative association between presence of a 
prescription monitoring program and claims rates for controlled-release oxycodone.40 
The findings indicate that PDMPs may reduce the number of prescriptions of controlled-
release oxycodone. Although this finding can’t be generalized to all prescription drugs, the 
indication does warrant further investigation into other prescription drugs. However, the study 
did not find the same results in two additional models which included other explanatory 
variables, thus the results must be taken with caution. 
A study from 2009 looked at the association between state shipments of prescription 
opioids and prescription opioid treatment admission rates, and the impact of PDMPs on 
prescription opioid treatment admission rates.44 The authors found that increases in state 
shipments of prescription opioids were associated with increased treatment admissions.44  They 
also found that states with PDMPs had lower shipment rates and slower increases in prescription 
opioid admissions over the study period compared to those without.44 This study is another 
example of research indicating reduced access to prescription drugs associated with PDMPs.   
A 2010 evaluation of the Kentucky All Schedule Prescription Electronic Reporting 
System (KASPER), which is Kentucky’s PDMP, investigated opinions by program utilizers on 
the effectiveness of KASPER.34 The study focused on pharmacists, prescribers and law 
enforcement agents as these were viewed as the “key user groups”.34 Surveys were given in two 
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formats: mailed survey packets and online surveys.34 Pharmacists and prescribers were given the 
choice between the two methods, although law enforcement agents were only presented with the 
online survey option.34 The authors found that more than 90% of pharmacists, prescribers and 
law enforcement agents perceived KASPER as effective in preventing drug abuse and diversion, 
and reducing doctor shopping.34 The study also found that substance abuse admission rates for 
prescription opioid abuse have risen significantly in the years after the KASPER system was 
established.34 
The study is beneficial in providing insight into the effects that KASPER is having on the 
prescription drug epidemic in the Commonwealth. The system appears to be perceived as 
effective by stakeholders and the study shows an increase in admissions rates for prescription 
opioids, which may indicate that at least some drug misusers are turning toward treatment for 
their addiction as access to prescription drugs is reduced. For future research, it may be 
beneficial to investigate access to substance abuse treatment and if the state is meeting the new 
demand that may be driven by the KASPER system. Additionally, it may be helpful to monitor 
the success of prescription drug addiction treatment and what recovering substance abusers do 
after treatment. Following these individuals overtime may give insight as to the characteristics 
that promote successful treatment outcomes, which programs work best, and what types of drugs 
these individuals use when/if they relapse. 
A 2012 study evaluated state trends in opioid abuse associated with PDMPs.43 The study 
used a prescription drug abuse surveillance system known as RADARS (Researched, Abuse, 
Diversion and Addiction-Related Surveillance) to determine opioid abuse across states between 
2003 and 2009. States were grouped into three categories: (a) PDMP in place during the entire 
study period; (b) No PDMP in place during the entire study period; and (c) PDMP became 
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operational during the study period.43 The findings of the study indicated that PDMPs were 
associated with a reduction in growth rates of opioid abuse and misuse over time.43 This was true 
for both the general population and the population seeking treatment for substance abuse 
(analyses were conducted for each).43  
The study provided important insight in that PDMPs appear to be associated with change 
in behavior. They were shown to be associated with reductions in opioid abuse and misuse. It 
should be cautioned when interpreting the results that these findings are only for abuse and 
misuse of prescription opioids. They do not consider factors such as shifts in drug use and 
misuse to other substances that are not monitored by PDMPs. Research investigating the overall 
changes in drug abuse and misuse associated with PDMPs for all drug categories may give a 
better picture of what is actually occurring in states post PDMP implementation in terms of 
overall drug abuse and misuse. 
 
Recommendations for Future Evaluations 
Although the above studies provide great insight into the effectiveness of PDMPs, there 
are several areas of research that have not been investigated that could prove very important in 
terms of understanding the effects of these programs on substance use and related outcomes. 
First, programs vary significantly in terms of frequency of data collection, mandate, authorized 
users, and other factors described in the previous characteristics section of this paper. None of 
the national studies take all or often any of these factors into account in their analyses. 
Understanding which characteristics of PDMPs are associated with the greatest positive impact 
on relevant outcomes is important in moving forward and establishing these systems nationally. 
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This will allow states with weaker PDMPs to model after other states with better PDMP models 
and in turn put in place the most effective system possible. 
 Another interesting area of research that has not received much attention is regional 
variation in the impact of PDMPs within a state. Certain regional characteristics such as 
proximity to state borders, rural vs. urban settings, etc. may play a role in how effective PDMPs 
are and may be worth investigation. It may be that individuals who are closer in proximity to 
state borders are more easily able to circumvent their state’s PDMP by going to practitioners in 
neighboring states. 
 It may also be beneficial for future evaluations of PDMPs to consider the impact they 
may have on illicit substance use, such as heroin and cocaine. The most commonly abused 
prescription drugs are opioids, such as hydrocodone (Vicodin) and oxycodone (OxyContin).1 
Given the similar euphoric and other effects that heroin and prescription opioids share, addicts 
may turn to heroin due to a reduction in access to prescription opioids associated with 
implementation of PDMPs.28 Heroin is an illicit substance and thus obtained in forms that are 
unregulated, may contain toxic contaminants, and vary in purity or concentration.3,47 The shift 
from prescription opiates to heroin could result in worse health outcomes and other costs to the 
drug abusing population and society as a whole. Additionally, ignoring these effects may lead to 
evaluations that overestimate the benefit of PDMPs and fail to address the need for concurrent 
programs that prevent drug abuse shift from prescription to illicit substances. Future evaluations 
should be conducted to determine these effects and incorporate them into the evaluations of 
PDMPs with recommendations for policies that may help avert this shift. 
 Finally, many of the studies evaluating PDMPs used the TEDS data set for their analyses, 
likely because the state level data are public and easily accessed for this data set. It would be 
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interesting, however, if other data sets were used to attempt to understand the impact that 
PDMPs have on prescription-related overdoses, mortality, and crime rates. The topic area is 
currently relevant and additional national studies need to be conducted to determine the full 
effect of these programs. Research in this topic area will not only help understand the policy 
implications of PDMPs, but also under what circumstances and implementation strategies 
PDMPs are most effective. 
 
ABUSE-DETERRENT FORMULATIONS 
 Abuse-deterrent formulations of prescription opioids are designed to deter potential 
abusers from consuming these medications in ways unintended by the manufacturer. Many 
abusers of prescription opioids prefer to use non-oral routes, such as inhalation, smoking and 
injection, to consume prescription opioids because this allows for faster and more intense onset 
of euphoria and other desired effects.14,48 Therefore, abuse-deterrent formulations typically 
attempt to make it more difficult for abusers to effectively use the drug in non-oral routes and 
achieve the desired effects. There are two main approaches to abuse-deterrent formulation used 
in prescription opioids currently on the market. These are a) opioid agonist/antagonist 
combinations and b) formulations with agents that make crushing and dissolving more 
difficult.49,50 
 
Characteristics of Abuse-Deterrent Formulations 
 Development of formulations of prescription opioids that also contain opioid antagonists 
work to prevent abuse by blocking the euphoric effects of the drugs when used in ways other 
than those intended by the manufacturer.51 Opioid agonists are drugs that bind to opioid 
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receptors in the brain and activate them, resulting in the pain relieving and other effects that are 
felt when these drugs are taken51. Opioid antagonists bind to the same receptors as opioid 
agonists, however, they do not activate the receptors and typically block opioid agonists from 
binding.51 Manufacturers of this type of abuse-deterrent formulation design the drugs so that the 
antagonist is only absorbed into the users systems if the drug is tampered with, such as being 
crushed, chewed, or dissolved. When tampered with, the antagonist is absorbed into the users 
system and blocks the positive effects of the agonist. Conversely, if the drug is taken properly the 
agonist is absorbed and the antagonist passes through the users system with no or minimal 
absorption, allowing the agonist to operate as intended. Examples of prescription opioid using 
this type of abuse-deterrent formulation that are currently on the market include: Targiniq ER, a 
formulation of extended-release oxycodone and the opioid antagonist naloxone; and Embeda, an 
extended-release morphine that contains the opioid antagonist naltrexone.50,52 
 The other method of abuse-deterrent formulation currently used in the market is 
formulations with agents that make crushing and dissolving more difficult. Typically, these 
formulations contain agents that make it more difficult to crush the drug into powder for snorting 
or smoking, and when crushed and/or dissolved creates a viscous gel that is difficult to inject. 
Examples of this type of abuse-deterrent formulation are OxyContin ER (extended-release 
oxycodone), Hysingla ER (extended-release hydrocodone), and Zohydro ER (extended-release 
hydrocodone). 
 
Evaluation and Impact of Abuse-Deterrent Formulations 
 Although all new drugs marketed as abuse-deterrent formulations are required to conduct 
research on the association between the new formulation and clinical outcomes associated with 
  
  Branham 
18 
abuse, these formulations are relatively new and therefore fewer studies have been published that 
evaluate their impact on drug use behavior.50,52 One abuse-deterrent formulation that is of 
particular interest due to high abuse potential and the significant body of literature examining it 
relative to other abuse-deterrent formulations is the reformulation of extended-release OxyContin 
(ER-OC) introduced in August 2010.15,17 Due to the significant amount of literature associated 
with the introduction of this abuse-deterrent formulation and the lack of literature available for 
other abuse-deterrent formulations, this section focuses on the introduction of this specific abuse-
deterrent formulation. 
 OxyContin was introduced into the U.S. market in 1996 and was aggressively marketed 
and promoted for use in treating moderate to severe pain.53–55 Sales of OxyContin grew quickly 
and by 2004 OxyContin had become the most abused prescription drug in the U.S.54,56 Abuse by 
non-oral routes, such as snorting, smoking and injecting, is common among OxyContin 
abusers.57–59  
 The introduction of the abuse-deterrent form of ER-OC, which made use of the drug by 
non-oral routes more difficult, has been shown to be successful in reducing abuse of ER-OC.19–22 
One study found that within two years of the introduction of reformulated ER-OC, non-oral 
abuse decreased by 66% and oral abuse decreased by 41% among individuals assessed for 
substance abuse treatment.21 Another study found that reported fatalities involving ER-OC 
decreased by 82% within three years of the introduction of reformulated ER-OC.22 A study of 
OxyContin users in a rural county in Kentucky found that prevalence of abuse of reformulated 
ER-OC was significantly lower than that of the original formulation of ER-OC (33% vs. 74%).19 
Finally, a poison control centers study found that reports of ER-OC abuse exposures decreased 
by 32% after the introduction of reformulated ER-OC.20 
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 These studies indicate that it is likely, at least for ER-OC, that the introduction of abuse-
deterrent formulations can have the desired effect of deterring abuse of the specific prescription 
opioids in question. However, the narrow focus of these studies also leaves the question of 
whether users are actually reducing overall abuse of prescription opioids or shifting their use to 
alternative substances. 
 A few studies have investigated whether the introduction of reformulated ER-OC has 
been associated with increases in abuse of other opioids such as heroin and buprenorphine 
among OxyContin users. One study showed that since the introduction of reformulated 
OxyContin, the level of reported heroin exposures to poison centers increased by 37% by 2012, 
while ER-OC exposures decreased by 26%.17 Another study of opioid users entering substance 
abuse treatment found that reporting OxyContin as the primary drug of abuse decreased from 
35.6% before the introduction of reformulated ER-OC to 12.8% after, while past 30 day heroin 
use to get high doubled during the same study period.18 Additionally, a study of opioid users 
entering substance abuse treatment showed a significant reduction in past month OxyContin 
abuse after the introduction of ER-OC (45% to 26%), while past month use of heroin rose from 
less than 30% to 50% during the study period.12 Finally, a time-series analysis of patients 
presenting for treatment found significant increases in abuse of buprenorphine after introduction 
of reformulated ER-OC.60 
 These studies indicate that there may be some shift occurring when abuse-deterrent 
formulations are introduced into the market. However, they generally focus on a subset of the 
prescription opioid-using population. Most of these studies take advantage of substance abuse 
treatment data, which likely does not give a depiction of the impact of abuse-deterrent 
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formulations on the prescription opioid using population as whole, as only a small portion of 
opioid users actually seek treatment.  
  
Recommendations for Future Evaluations 
 Few studies have evaluated the impact of abuse-deterrent formulations on drug use 
behavior other than examining the impact these policies have on abuse of the specific 
prescription opioid targeted by each new formulation. There is still debate as to whether or not 
the introduction of various abuse-deterrent formulations, such as ER-OC, actually result in shifts 
to other opioids, particularly heroin.61 A recent study comparing past year users of heroin and/or 
prescription painkillers found that heroin users were more likely to be involved in criminal 
activity, have poorer mental and physical health, and were less economically stable.27 This 
implies that if shifting from prescription opioids to heroin or increasing the frequency of heroin 
use among opioid users is occurring, this may result in negative health and other consequences 
on users. Examining the population of non-medical prescription opioid users over time would 
prove beneficial to understand how the population changes after the introduction of these 
formulations.  
 Additionally, previous studies have focused on opioid users entering or being evaluated 
for treatment, which only represents a small proportion of opioid users.62 No studies have used a 
nationally representative sample to evaluate the impact of introducing abuse-deterrent 
formulations on prescription opioid users in terms of shifts in patterns of opioid use other than 
the targeted prescription opioid. Future research should take a broad approach and consider 
patterns of use of multiple types of opioids and other commonly abused substances in the 
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 The need for further understanding of the prescription opioid population is abundantly 
clear. This population is difficult to follow over time and the current atmosphere of introducing 
many different policies to avert the prescription opioid epidemic makes determining how these 
policies impact overall opioid use difficult. Efforts to curb prescription opioid use such as 
development of PDMPs and abuse-deterrent formulations are likely influencing drug use 
behavior in prescription opioid users beyond just how they use prescription opioids. Narrowing 
down a change in a population and associating it with a single specific policy is difficult. 
However, even if this cannot be achieved, it may still be beneficial to study the patterns of 
substance use among prescription opioid users since the beginning of the increased introduction 
of these types of policies in order to better understand the drug use patterns in this population 
and how they have changed during this time period. 
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CHAPTER III: PAPER 2 
 
TITLE: Changes in Demographic Characteristics and Drug Use among Non-Medical 
Prescription Opioid Users, 2005-2014 
 
INTRODUCTION 
 Use of prescription opioids for non-medical purposes has become a major problem in the 
U.S in recent decades.4–7 Between 1999 and 2007, the number of opioid analgesic associated 
unintentional overdose deaths rose from less than 4,000 to nearly 12,000 annual deaths, while 
during the same time period treatment admissions for prescription opioids nearly quadrupled.7,8 
Drug overdose deaths are now the number one cause of accidental death in the U.S., with 40% of 
all accidental deaths being a result of prescription opioid use.9  
The growth in the problem of nonmedical use of prescription opioids is, at least in part, a 
result of the rise in the number of prescriptions for opioids that occurred in the 1990s and early 
2000s.7,63,64 In response to the growing epidemic, several intervention efforts have been 
developed to prevent overprescribing and decrease access to and/or the potential abuse of 
prescription drugs. One intervention is the development of prescription drug monitoring 
programs (PDMPs). These programs monitor prescribing behaviors of doctors and patients and 
are designed and implemented at the state level.13,33 PDMPs help health care professions and 
monitoring organizations prevent doctor shopping, overprescribing, diversion and drug 
abuse.13,33 Several studies have shown PDMPs to be associated with improved prescription drug 
use outcomes, including slowed growth in prescription drug supply, and decreased treatment 
rates, prescription rates and poison center calls.28,34,39–45 Since 2000, the number of states with 
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PDMPs has increase substantially and currently all but one state has some form of PDMP in 
place.33 
Another important effort in the prevention of non-medical use of prescription opioids has 
been the development of abuse-deterrent formulations of prescription drugs. Many non-medical 
users of prescription opioids consume the drugs using non-oral routes, such as inhalation, 
smoking and injection.14,48 Abuse-deterrent formulations are designed to make non-oral use of 
prescription drugs more difficult.14,48 Typical methods include: a) combining an opioid 
antagonist with the prescription opioid that only activates when efforts to use the drug non-orally 
are made; and b) formulations with agents that make crushing and dissolving the drug more 
difficult.48,50–52 These formulations have become very common in the past five to ten years and 
examples include extended-release (ER) OxyContin, Hysingla ER, Zohydro ER, Targiniq ER, 
and Embeda.48,50–52 Many of these drugs are relatively new and substantial research evaluating 
their impact on prescription drug use does not exist for most.  
One reformulation that has been studied extensively is ER OxyContin. Studies have 
associated the introduction of ER OxyContin with significant decreases in both non-oral and oral 
misuse of the drug and decreases in reported fatalities.19–22 Several studies have also indicated 
that the introduction of the formulation may be associated with increases in use of other drugs, in 
particular heroin.12,17,18,60 
In addition to the growing problem of non-medical prescription opioid use, the past 
decade or so has seen increases in heroin access and use. The Substance Abuse and Mental 
Health Services Administration (SAMHSA) estimates that the number of individuals using 
heroin in the past 12 months nearly doubled between 2007 and 2013, while heroin dependence 
more than doubled in the same time frame.65 Increases in perceived ease of availability of heroin 
  
  Branham 
24 
were also shown among heroin users in the same study.65 Other studies have also indicated that 
the concentration of heroin in the U.S. illicit market has been on the rise and prices of heroin on 
the decline in recent years.66,67 
The combination of increased prescription opioid related policy and availability of illicit 
substance alternatives, especially heroin, may have had an influence on the prescription opioid 
using population in terms of demographic makeup and drug use behavior, as the policies create 
barriers to access to prescription opioids and access to heroin provides a viable alternative. 
Certain populations may be more or less likely to continue prescription opioid use when faced 
with policies that reduce access to them. Additionally, some users may begin using other drug 
alternatives, such as heroin, to compensate for the reduced access to prescription opioids. This 
means that the demographic composition and drug use patterns of the prescription opioid using 
population may be very different now than they were a decade ago. 
 Recent studies of the prescription opioid population have shown increases in prescription 
opioid use disorder, frequency of prescription opioid use, drug overdose deaths, and increased 
heroin use in recent years.6,68,69  However, no studies to the authors’ knowledge have 
investigated the non-medical prescription opioid using population in terms of changes in a 
variety of demographic characteristics and alternative drug use, over the past decade. Increased 
heroin use in recent years has been indicated in some previous studies.31,69 However, other 
potential substitute substances, such as cocaine and alcohol, have not been examined across time. 
It may be beneficial to understand how the demographic characteristics and drug use behavior 
differ in recent years in order to better understand the target population for interventions and 
policies targeting non-medical users of prescription opioids. Examining these factors may also 
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inform and give insight into the potential influence current opioid policies have on the 
prescription opioid using population and areas where further research may be needed.  
 In order to better understand the prescription opioid using population and how it has 
changed in recent years, this study aims to: a) describe the demographic characteristics and use 
of various categories of drugs among prescription opioid users; and b) compare these differences 




Data on substance use were obtained from the National Survey on Drug Use and Health 
(NSDUH) public use files for years 2005 through 2014. The NSDUH is an annual survey 
conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA).70 
The survey can be used to estimate drug use and mental health status at both the national and 
state level. The survey involves approximately 70,000 in-person, computer assisted interviews 
with a random sample of the civilian, non-institutionalized population of the U.S. that is 12 years 
of age or older. The overall response rate for each year included in the study was between 70% 
and 80%.  
Each public use file contains data for a single year of survey data. Public use files were 
grouped in two year intervals for ease of comparison of data from different time periods, as the 
goal of the study was to identify trends in demographic and drug use over time in the non-
medical opioid using population. The combinations were: 2005-2006, 2007-2008, 2009-2010, 
2011-2012, and 2013-2014.  
  
  Branham 
26 
Non-medical pain reliever (NMPR) is the term used in the NSDUH to refer to 
prescription opioids, as well as a few prescription drugs used to treat pain symptoms that do not 
act on the same receptors as opioids. However, the vast majority of those reporting NMPR use 
reported opioid NMPR use. In a previous study using the NSDUH it was shown that those 
reporting only non-opioid NMPR use represented n=36 across six years of survey data (2002-
2004 and 2008-2010) which represented a little more than 0.001% of the total sample of NMPR 
users.31 For this reason, the NMPR population is considered in this study to represent the non-
medical prescription opioid using population.  
 
Inclusion Criteria 
The NSDUH collects data on past 12 month use of various substances, including NMPR 
use. In order to be included in the analysis the respondent must have reported using NMPRs 
within the past 12 months. Further explanation of how this variable was calculated is provided 
below under the variables section. The final total sample size was 39,090, with year group 
sample sizes of 8,620 (2005-2006), 8,551 (2007-2008), 8,415 (2009-2010), 7,633 (2011-2012), 
and 5,871 (2013-2014). 
 
Variables 
Demographic variables compared across the years of survey data included metropolitan 
status, race/ethnicity (white non-Hispanic, black non-Hispanic, Hispanic of any race, and other), 
education, income, sex, age, health insurance (any health insurance vs. none), and marital status 
(currently married or living as married vs. single). Metropolitan status was defined in the 
NSDUH using the Office of Management and Budget (OMB) definitions.71 Education was 
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grouped by highest achievement with categories including: less than high school, high school, 
some college, and a category for 12-17 year olds, as they likely would not have had the 
opportunity to obtain any education other than less than high school. 
Variables describing past 12 month drug use of a variety of drug types were included in 
the study. These included: non-medical pain relievers, non-medical OxyContin, heroin, alcohol, 
cocaine, crack, stimulants, marijuana, sedatives, hallucinogens, and inhalants. The NSDUH 
asked respondents to choose the easiest way to describe the total number of days they used each 
substance in the past 12 months and gave them the options of days per week, days per month, or 
days per year. The survey included a variable for each substance which was created from the 
responses to these questions and defined the total number of days in the past 12 months the 
substance was used. These created variables were used to create a new variable that categorized 
the past 12 month use of each substance into four categories: none, 1-29 days, 30-89 days, and 
90+ days. A variable for injection drug use, defined as ever injecting any drug, was also included 
in the analysis. 
 
Analysis 
 Demographic and drug use variables were compared across year groupings. Chi-square 
was used to test for differences in each variable, with weighted percentage distributions and 
standard errors reported. Each year group was compared to the year group immediately 
preceding it, i.e. 2013-2014 vs. 2011-2012, and to the first year group in the study, i.e. 2005-
2006. All analyses were conducted using SAS 9.4. In order to adjust for the multi-stage complex 
survey design of the NSDUH, survey commands were used (PROC SURVEYFREQ) to allow 
strata, cluster and weight variables to be included in the analysis, providing appropriately 
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weighted estimates. Additionally, the DOMAIN statement was used to identify and account for 
the NMPR subpopulation within the NSDUH. 
 
RESULTS 
Table 1 describes the demographic characteristics of past 12 month non-medical pain 
reliever (NMPR) users. Both the 2011-2012 and the 2013-2014 year groups differed significantly 
at the α = 0.05 level from the 2005-2006 year group, with both appearing to have a smaller 
proportion of white non-Hispanics and greater proportions of the other race/ethnicity categories 
than the 2005-2006 year group. Additionally, the 2011-2012 year group differed significantly 
from the 2009-2010 year group in race/ethnicity, similarly with a smaller proportion of white 
non-Hispanics and a greater proportion of all other race/ethnicity categories. Figure 1 further 
describes these differences by showing the percentage of the population reporting any 
race/ethnicity other than white non-Hispanic. In this graph, a possible trend appears across year 
groups with the proportion of those reporting any race/ethnicity other than white non-Hispanic 
increasing with time (26.8% in 2005-2006 and 34.9% in 2013-2014). 
Table 1 also shows a statistically significant difference in age for all year groups when 
compared to 2005-2006. Figure 2 further portrays this difference, with a pattern of older 
individuals representing a greater proportion of the NMPR using population in later years (the 
50+ age group represented 9.8% in 2005-2006 and 17.6% in 2013-2014). It also appears that 
there may be a pattern in the education variable with those with any college making up a greater 
percentage of the population in later years (39.8% in 2005-2006 vs. 46.4% in 2013-2014). 
Table 2 describes past 12 month drug use for several categories of drugs among NMPR 
users. Significant differences were found in the number of days of NMPR use in the past 12 
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months, with the percentage of the population using for 30-89 days or 90+ days appearing to be 
greater in both the 2011-2012 (19.7% and 18.1%, respectively) and 2013-2014 (20.9% and 
19.8%, respectively) groups when compared to the 2005-2006 group (18.8% and 15.2%, 
respectively). These differences are shown graphically in Figure 3.  
OxyContin use also appeared to have significant differences among some year groups, 
with 2009-2010, 2011-2012, and 2013-2014 year groups all differing significantly from the 
2005-2006 year group. Figure 4 shows graphically the percentage of NMPR users using 
OxyContin one or more days in the past 12 months. The figure shows an initial increase from 
10.5% in the 2005-2006 year group to a peak in the 2009-2010 year group of 14.5% and then a 
decline in the following year groups to 12.3% in the 2013-2014 year group. 
Several other drugs were also shown to have significant differences among at least some 
year groups. Two noticeable patterns appear among these drugs. First, heroin use is significantly 
more common among NMPR users in the 2009-2010, 2011-2012, and 2013-2014 year groups 
(3.7%, 4.0%, and 5.4%, respectively) when compared to the 2005-2006 (2.5%). Figure 5 shows 
this pattern further. Although the majority of NMPR users still do not appear to use heroin, the 
difference between 2.5% in 2005-2006 and 5.4% in 2013-2014 is more than a two-fold increase 
in the proportion using heroin. A similar pattern appears with marijuana use, although to a lesser 
degree, with 2009-2010, 2011-2012, and 2013-2014 year groups all showing greater percentages 
of the population using marijuana (51.2%, 51.2%, and 50.7%, respectively) when compared to 
2005-2006 (48.4%).  
The second distinguishable pattern is that the percentage of NMPR users also using 
cocaine and/or crack appears to be smaller in all later year groups when compared to the 2005-
2006 year group. Figure 6 shows the trend in cocaine use among NMPR users. A steep drop 
  
  Branham 
30 
appears between 2005-2006 and 2009-2010, with any cocaine use in the past 12 months 
dropping from 20.2% to 16.0%. It appears that after this point the percentages stay similar in 
subsequent year groups, with 15.1% in 2011-2012 and 16.0% in 2013-2014. Finally, the 
percentage of NMPR users ever injecting drugs in the 2011-2012 and 2013-2014 year groups 
(8.8% and 9.4%, respectively) were significantly greater than the 2005-2006 group (6.9%). 
Figure 7 further shows this pattern. 
 
DISCUSSION 
 The results of the study indicate that when comparing the population of non-medical pain 
reliever (NMPR) users over the past decade, racial and ethnic diversity has increased, users are 
now older, frequency of NMPR use has increased, non-medical OxyContin use peaked around 
the middle of the study period and then began to drop, heroin use increased, cocaine use 
decreased, and injection drug use became more common. 
 There are a several possible factors that may contribute to the changes in distribution of 
the population’s characteristics and drug use across time. It is easiest to think of this in terms of 
use and non-use of NMPRs and how certain subgroups of users move from one of these states to 
the other. This is not a longitudinal study and therefore is not following the population over time. 
However, each year is assumed to be a nationally representative sample, and therefore the idea is 
that comparing the estimates from time period to time period gives us insight into these 
movement patterns.  
It may be that certain groups are being driven out of the NMPR using population at a 
faster rate than other. Studies have indicated that the rate of prescription opioid prescribing 
plateaued between 2010 and 2012, and abuse of NMPRs did the same between 2011 and 
  
  Branham 
31 
2013.69,72,73 These studies indicate that either those entering the NMPR population have slowed 
or those exiting have increased, or a combination of the two. Obviously, some users will exit the 
NMPR user population due to death, either associated with NMPRs or not. However, as previous 
studies have shown, the pattern of drug overdose associated deaths typically follow that of non-
medical drug use patterns, it is unlikely that this is the only explanation for possible increased 
exiting of the NMPR population.24,62  
Some NMPR users may stop using due to decreased access to prescription opioids as a 
result of policies decreasing access or ability to abuse. Some of these users may be inclined to 
quit non-medical drug use entirely, either through treatment or other means, or begin using other 
drugs in place of NMPRs. This theory is consistent with several previous studies showing that 
after implementation of prescription drug monitoring programs there was slowed growth in the 
supply of prescription drugs, decreased NMPR associated treatment raters, poison center calls, 
and prescription rates.28,34,39–44  
Similarly, studies have shown abuse-deterrent formulations to be associated with 
reductions in abuse of the targeted NMPR, decreased reporting of NMPR-associate fatalities, and 
fewer associated poison control center calls.19–22 These studies indicate some users may also be 
driven out of the NMPR user population due to factors associated with these intervention efforts. 
Many of these policies were implemented during the study period and the previous literature 
supporting the influences of these policies on NMPR users. Therefore, it is logical to theorize 
that they, at least in part, contribute to the changing demographic and drug use patterns.  
Additionally, certain groups may find it easier or more difficult to begin NMPR use in the 
changing prescription opioid environment. The results indicate that the age of users has increased 
from time period to time period in the study. It may be that as physicians prescribing NMPRs 
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have become more educated about the problems associated with NMPRs and addiction and 
programs like PDMPs force them to rethink their prescribing behavior. This may have led to 
increased hesitance to prescribe NMPRs and this hesitance may be more pronounced toward 
younger individuals than older, thus decreasing their ability to “doctor shop” and obtain NMPRs. 
Comparisons of time trends of prescribing of NMPRs stratified by age group would be beneficial 
in supporting or discrediting this theory. 
 Racial and ethnic diversity appeared significantly different when the 2011-2012 year 
group was compared to both the 2005-2006 and 2009-2010 year groups, with increased 
proportions of both black non-Hispanics and Hispanics represented in the 2011-2012 year group. 
This may be associated with the increased racial diversity in the U.S. population as a whole over 
the time period, or there may be some additional underlying factors that have yet to be identified 
that have had an influence. Further research to elucidate these factors is needed.  
 The study found that when compared to the 2005-2006 group, both the 2011-2012 and 
2013-2014 groups showed significant increases in frequency of any NMPR use. This indicates 
that either users staying in the NMPR group long-term are using more frequently over time, 
those entering the NMPR group in later years of the study are using at higher frequencies than 
those entering the NMPR group in earlier years, less frequent NMPR users are more likely to 
exit in later years of the study, or some combination of these. Given the tightening of NMPR 
policy and changing prescribing behavior of providers, it may be that more casual users of 
NMPRs are decreasing in number. NMPR users that use more frequently may show more 
resistance to quitting NMPRs even when faced with greater challenges obtaining them. This 
explanation is logical as high frequency NMPR users would be more likely to be dependent and 
to have more consistent prescription sources. 
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 Interestingly, non-medical OxyContin use peaked in the 2009-2010 year group and then 
showed declines afterword (Figure 4), though the declines in the subsequent year groups were 
not statistically different from the year group immediately preceding it. This peak coincides 
closely with the introduction of abuse-deterrent reformulation of OxyContin.15,17 The findings 
cannot be attributed to or associated with the introduction of the abuse-deterrent OxyContin, 
however, they are worth noting. 
 Frequency of heroin use was shown to increase over the study period, which is consistent 
with a growing body of literature showing the increase in heroin use in the U.S. and the 
association between prescription opioid use and subsequent heroin initiation and use.26,29–
31,68,69,74,75 These two factors combined should lead one to predict that if heroin use is increasing 
and at the same time prescription opioid use typically precedes heroin initiation, then across the 
time period there would be growth in the proportion of NMPR users also using heroin. 
Coinciding with this increase in the frequency of heroin use was an increase in ever having 
injected drugs. These results are expected as heroin is frequently used via injection, while NMPR 
users use this route less often.70,76  
 Finally, both cocaine and crack showed declines in past 12 month use over the study 
period. It is difficult to discern the reasoning for such results given the scope of the study. 
Similar to the theory described above, it may be that casual multi-drug users have been more 
likely to exit or less likely to enter the NMPR using population over the study period due to 
barriers, while heavy opioid only users have been more likely to continue use. Further research 
examining classes of non-medical drug users across multiple drug types could aid in further 
explanation of these results. 
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Limitations 
 There are several limitations to the study. The cross-sectional design of the study is a 
hindrance to drawing conclusions about patterns across time. The study does not follow the same 
individuals across time and therefore change in individual behavior cannot be ascertained; only 
comparing distributions across time period for significant difference and making inferences 
about what those differences could potentially mean can be done with this study.  
Additionally, we cannot say any particular policy was the cause of changes or is even 
associated with them, this can only be theorized about given the results. Also, no state-level 
variables were available in the public use files of the NSDUH and given that there are many 
factors across states that may impact NMPR users over time, none of these factors can be 
accounted for. Having state-level variables would also be beneficial to allow for studying drug 
policy implications within individual states, for example PDMPs, which are implemented at the 




 The study indicated that the NMPR using population is evolving across demographic 
characteristics and drug use. Future analyses investigating drug use patterns in subgroups of 
prescription opioid users may be valuable as different subgroups may react differently to policies 
and other factors. Additionally, some policies or interventions like abuse-deterrent 
(re)formulations may be more or less successful in deterring non-medical use than others and 
thus evaluations of these policies separately would be valuable, but difficult unless planned in 
advance. Stratified analyses for different subgroups of prescription opioid users in terms of 
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quantity used may also prove valuable as it is likely that infrequent and frequent prescription 
opioid users are not the same across all factors and characteristics. Finally, studies looking at 
multiple opioid use and how this has changed over time and what opioids are commonly being 
used in conjunction with each other may give insight to which opioids should be targeted in 
future policy. 
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CHAPTER IV: PAPER 3 
 
TITLE: Trends in heroin use and initiation among non-medical prescription opioid users 
in the U.S., 2005-2014 
 
INTRODUCTION 
Opioid abuse, including both prescription opioids and heroin, has been become a major 
public health issue in recent decades. As of 2014, drug overdose is the leading cause of 
accidental death in the U.S.9 Of the 47,055 lethal drug overdoses in 2014, 18,893 (40%) were 
related to prescription opioids, while 10,574 (22%) were related to heroin.9 In addition to 
growing overdose deaths, sales of prescription pain relievers and substance use treatment 
admissions have been on the rise, with sales of prescription opioids seeing a four-fold increase 
between 1999 and 2010, and substance use disorder treatment admission rates six times larger in 
2009 compared to 1999.10 Finally, the concentration of heroin in the U.S. market has been on the 
rise, while the street price of heroin has been shown to be on the decline in recent years, and 
there has been increase in perceived availability of heroin among users.65–67 
Several policies and programs have been developed in recent years to address the 
growing opioid problem in the U.S. These policies and programs have heavily focused on 
restricting access to prescription drugs (prescription drug monitoring programs) or decreasing the 
abuse potential of prescription drugs (i.e. development of abuse-deterrent formulations of 
prescription drugs).11–16 Several studies have indicated that these programs are associated with 
reductions in non-medical prescription opioid use and related overdose rates.17–22 Some studies 
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have also indicated that these policies may be driving at least some prescription opioid users to 
begin using heroin.12,18,22  
Heroin and prescription opioids operate on the same receptors in the body and, in turn, 
produce similar euphoric effects.28,51,77 Previous studies have suggested prescription opioids may 
function as “gateway” drugs to heroin; and prescription drug use typically precedes heroin 
initiation, whereas the reverse is far less common.25,26,29,30,78,79 Given the decreased access to 
prescription opioids and barriers to non-medical use created by recent prescription drug policies, 
in conjunction with increased access and decreasing costs for heroin, there may now exist a 
stronger incentive for prescription opioid users to use heroin. 
One prescription opioid of particular interest is OxyContin, which was introduced in 
1996 for treatment of moderate to severe pain.53–55 OxyContin rapidly became a popular drug 
and by 2004 was the most abused prescription drug in the U.S.54,56 In response to this, an abuse-
deterrent version of OxyContin was introduced in August 2010.15,17 Literature has indicated that 
the reformulation has been associated with decreased reporting of OxyContin as the primary 
drug of abuse, increased heroin exposure calls to poison centers, and increased heroin use among 
those presenting at heroin treatment centers.12,17,18,60 
The National Survey on Drug Use and Health (NSDUH) is an annual nationally 
representative survey of the civilian, non-institutionalized population of the U.S.,12 years of age 
or older.70 The survey obtains information on respondents’ mental health status, demographic 
characteristics, and drug use behavior over the past year for a broad spectrum of drugs, including 
prescription pain relievers and heroin. The NSDUH also includes a section devoted entirely to 
non-medical use of OxyContin that includes the same set of questions asked about in the other 
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drug sections. This provides a unique opportunity to study this subgroup of prescription opioid 
users separately from non-OxyContin non-medical prescription opioid users. 
Since not all prescription opioids are the same in terms of potency, abuse potential, and 
risk, and because an OxyContin-specific reformulation has been developed, analyses 
investigating trends in demographic characteristics and drug use over time among non-medical 
OxyContin users may be beneficial. Studying this subgroup of NMPR users may provide some 
insight into how recent opioid policy and the changing opioid environment (access, cost, 
increased access to heroin, etc.) have influenced the characteristics and behaviors of the non-
medical OxyContin using population.  
Given the relationship between prescription opioid and heroin use, investigation of heroin 
use specifically and how it differs across time in the non-medical OxyContin using population 
may provide valuable information about the evolving opioid using population. Studies have 
evaluated heroin use among non-medical prescription opioid users.29–31 However, no studies, to 
the authors’ knowledge, have investigated how non-medical OxyContin users differ from other 
non-medical opioid users in terms of heroin use over time.  
Investigating these factors over the past decade may not only inform intervention and 
treatment efforts, but also give insight into potential negative externalities associated with 
prescription opioid targeted policies that do not concurrently address the potential for users to 
begin use of more harmful substances. The findings may promote and inform development and 
implementation of policies that address substance abuse from a systems perspective rather than 
targeting individual categories of substances without consideration of other substances as 
potential replacements. 
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In order to address the issues described above, the following study aims to: a) describe 
heroin use behavior among non-medical OxyContin users compared to other non-medical 
prescription opioid users; and b) compare these differences from year-to-year over the past 
decade. The author hypothesizes that heroin use increased over the past decade for both non-
medical OxyContin and other non-medical prescription opioid users. However, this growth is 
expected to be more pronounced among non-medical OxyContin users around the time of 




The National Survey on Drug Use and Health (NSDUH) public use files for years 2005 
through 2014 were used for all analyses. The NSDUH is an annual survey conducted by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) that obtains 
information on drug use and mental health status and can be used to calculate national and state 
level estimates.70 The survey is given in-person with computer assistance annually to 
approximately 70,000 interviewees. The survey is designed to obtain a nationally representative 
random sample of the civilian, non-institutionalized population of the U.S. that is 12 years of age 
and older. Response rates for each year included in the study are 70% or greater.  
A public use file was accessed and downloaded for each of the years 2005 through 2013 
through the Inter-university Consortium for Political and Social Research (ICPSR) website.80 
ICPSR is the data stewardship organization currently used by SAMHSA to house their public use 
files. SAMHSA was contacted directly for the 2014 public use file because this public use file 
was not yet available through ICPSR at the time of the study. SAMHSA mailed the data, 
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codebook and other materials to the authors. A variable within each dataset identified the year of 
data and all public use files were combined using SAS to create a single dataset. 
Non-medical pain reliever (NMPR) is the term used in the NSDUH to refer to 
prescription opioids and a few non-opioid prescription drugs that are also used to treat pain 
symptoms. The majority of those reporting NMPR use reported opioid NMPR use. In a previous 
study using the NSDUH, those reporting only non-opioid NMPR use represented n=36 across six 
years of survey data (2002-2004 and 2008-2010) which represents less than 0.002% of the total 
sample of NMPR users.31 For this reason, the NMPR population is considered synonymous with 
the non-medical prescription opioid using population for the purposes of this study.  
 
Inclusion Criteria 
 All observations within the dataset were used in the analyses. Respondents were stratified 
into one of three groups based on their response to questions about NMPR and non-medical 
OxyContin use in the past 12 months (detailed explanation provided in the Variables section 
below). The three groups were: NMPR users using OxyContin (NMPR-O), NMPR users not 
using OxyContin (NMPR-N), and those not using NMPRs of any kind in the past 12 months 
(NMPR-X). All analyses were conducted for each of the three separate groups. The total sample 
size was 558,372 for all years of combined data with the stratified groups having the following 
sample sizes: NMPR-O (N = 5,861), NMPR-N (N = 33,229), and NMPR-X (N = 519,282).  
Details of the sample size by year and NMPR group can be found in Table 1. The decision to 
include the NMPR-X group in the analysis was to provide the ability to identify heroin use trends 
in this population and make comparisons to those of NMPR users. 
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Variables 
 The NSDUH asks respondents a set of questions about drug use for many different 
categories of drugs, including NMPRs (as well as a separate section for OxyContin, a type of 
NMPR), heroin, alcohol, marijuana, and cocaine, among others. One set of questions, included in 
each drug use section, asks about past 12 month use of each respective drug. Respondents are 
asked to choose the easiest way to describe the total number of days they used each substance in 
the past 12 months with the options: days per week, days per month, or days per year. The 
NSDUH uses the responses to these variables to calculate a new dichotomous variable for 
whether the person used the drug within the past 12 months (Yes/No). These variables were used 
to identify NMPR, non-medical OxyContin, heroin, heavy alcohol, marijuana, and cocaine use in 
the analyses. 
 The responses to the past 12 month use of NMPRs and OxyContin were used to stratify 
the sample. For the three stratification groups the following combinations of responses were used 
to determine which group to assign each respondent:  
 
   Past 12 month NMPR use Past 12 month OxyContin use 
NMPR-O    -    YES 
NMPR-N   YES    NO 
NMPR-X   NO    NO 
 
 The two primary dependent variables of interest for each of the stratified analyses were a) 
heroin use in the past 12 months and b) recent heroin initiation. The first paragraph of this 
section describes how all past 12 month drug use variables were created. A variable identifying 
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recent heroin initiation was created from a recoded variable in the NSDUH that identifies what 
the year of first use of heroin is, if that year is the same as the survey, the year prior to the year of 
the survey, or two years prior to the year of the survey. This variable was derived from responses 
during the interviews to questions “Did you first use heroin in [CURRENT YEAR - 1] or 
[CURRENT YEAR]?” and “Did you first use heroin in [CURRENT YEAR - 2] or [CURRENT 
YEAR - 1]?” Recent heroin initiation was defined as having first used heroin in the same year of 
the survey or the year immediately prior to the survey.  
 The initial goal was to create a variable that showed if the respondent initiated heroin in 
the past 12 months. Although the public use files of the NSDUH do provide a variable for month 
of first heroin use, they do not provide a variable for the month the survey was completed. Given 
these facts, if recent heroin use was defined as having first used heroin in the same year of the 
survey, not all of those initiating heroin in the past 12 months would be captured. The decision 
was made to define the variable for recent heroin initiation as those who initiated in the year of 
the survey or the year immediately prior to the survey. The authors believe this decision is 
justified given that the aims of the study are not to provide prevalence estimates but simply look 
at associations and compare percentage distributions of stratified groups across survey years. 
Additionally, prior research has indicated that, at least in recent years, heroin initiation is 
frequently preceded by NMPR use, while it is very uncommon for NMPR initiation to be 
preceded by heroin initiation.29 Therefore, it is likely that a substantial majority of NMPR users 
that recently initiated heroin according to the definition used in this study were NMPR users 
before heroin initiation. 
 The primary independent variable of interest was year of survey completion, as the aim 
of the study was to investigate heroin use and recent initiation in the stratified groups across time 
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to see if a positive relationship appeared and if there was a difference in the strength of these 
relationships depending on NMPR and non-medical OxyContin use status. Year was treated as a 
categorical variable in the analyses, with 2005 functioning as the reference year. The decision to 
do so was made so that odds ratios could be calculated for each year comparison. This allowed 
for identification of specific year differences in odds of heroin use or recent initiation, rather than 
just identifying if there was a positive association between increase in year and odds of using 
heroin in the past 12 months/ recently initiating heroin use, which would have been the case if 
year had been treated as continuous. 
 Variables identifying past 12 month heavy alcohol, marijuana, and cocaine use were 
included as independent variables. These were calculated using the method described in the first 
paragraph of this section. Additionally, a variable for whether the respondent had ever injected 
any drug was included as an independent variable. 
 Demographic and population characteristics included as control variables in the analyses 
were: age, race/ethnicity, income, sex, marital status, and health insurance status. Health 
insurance was included due to recent legislation expanding health insurance coverage in the 
United States through the Affordable Care Act (ACA) which may influence access to and use of 
prescription drugs and heroin differently across years and therefore should be accounted for. A 
categorized variable was used for age because the NSDUH does not provide the raw age of 
respondents in the public use files. It was also beneficial to use categorization of age to identify 
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Analysis 
 Descriptive statistics were calculated for each year across each variable in the study. The 
analyses were stratified by NMPR group (i.e. NMPR-O, NMPR-N, and NMPR-X). Chi-square 
tests were used to compare each variable across time. For each variable, each year was compared 
to the year immediately preceding it, i.e. 2014 vs. 2013, and to the first year (reference year) in 
the study, i.e. 2014 vs. 2005. Weighted percentage distributions and standard errors were 
reported. 
 Unadjusted analyses were conducted for the two outcomes: a) recent heroin initiation and 
b) past 12 month heroin use, and each independent variable. These analyses were stratified by 
NMPR group. Odds ratios and associated 95% confidence interval were reported. Finally, 
logistic regression was used to estimate adjusted odds ratios and 95% confidence intervals.  
 All analyses were conducted using SAS 9.4. In order to adjust for the multi-stage 
complex survey design of the NSDUH, survey commands were used (PROC SURVEYFREQ 
and PROC SURVEYLOGISTIC) to allow strata, cluster and weight variables to be included in 
the analysis, providing appropriately weighted estimates. Additionally, the DOMAIN statement 
was used to identify and account for the stratified subpopulations of interest within the NSDUH 
(i.e. NMPR-O, NMPR-N, and NMPR-X). The DOMAIN statement is the appropriate command 
to use in these instances as it allows for separate analyses for each domain to be performed and at 
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RESULTS 
 Descriptive statistics for each NMPR group by year for the each variable in the study are 
provided in Table 3, with percentages and associated standard errors (SEs) reported.  
 Clear trends in recent heroin initiation do not appear for any of the stratified populations. 
However, among the NMPR-N group there was a significant increase in the percentage reporting 
recent heroin initiation from 2008 (0.2%, SE = 0.1) to 2009 (0.8%, SE = 0.2) that remained 
similar in subsequent years. Similarly, another significant increase in this group occurred from 
2013 (0.9%, SE = 0.3) to 2014 (2.2%, SE = 0.5). 
 The percentage of non-medical OxyContin (NMPR-O group) users reporting past 12 
month heroin use was significantly higher in 2011 (17.1%, SE = 2.9) compared to 2005 (10.0%, 
SE = 1.7). Subsequent years stayed relatively similar when compared to 2005, except a non-
significant decrease in reported past 12 month heroin use between 2013 (18.1%, SE = 2.7) and 
2014 (15.6%, SE = 2.8), which resulted in the 2014 to 2005 comparison to no longer be 
significant at the α = 0.05 level. In contrast, both the 2013 to 2014 and the 2005 to 2014 
comparisons showed significant increases for both the other NMPR groups. Of respondents in 
the NMPR-N group for 2005, 1.1% (SE = 0.3) reported using heroin in the past 12 months, while 
those percentages were 2.7% (SE = 0.4) and 4.9% (SE = 0.7) in 2013 and 2014, respectively. In 
the NMPR-X group, values for 2005 (0.059% SE = 0.012) and 2013 (0.055% SE = 0.01) were 
similar, however, 2014 showed a significant increase (0.135%, SE = 0.023) in those reporting 
heroin use in the past 12 months. Overall, heroin use was much more common among the 
NMPR-O group (range: 3.2% – 7.8%) compared to both the NMPR-N (range: 0.2% - 2.2%) and 
NMPR-X (range: 0.01% - 0.04%) groups for all years. 
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 Past 12 month heavy alcohol use appeared to drop among the NMPR-O group from 2005 
(41.0%, SE = 3.4) to 2006 (31.4%, SE = 3.1) and remained at similar or lower values in 
subsequent years. Later years appeared to show modest but mostly significant decreases in heavy 
alcohol consumption relative to 2005 (22.9%, SE = 1.2), with 2011 and all subsequent years 
having estimates below 20%. Also of note, heavy alcohol use was more common among the 
NMPR-O group (range: 24.3% - 41.0%) in comparison to the NMPR-N group (range: 18.0% - 
24.3%) and the NMPR-X group (range: 5.6% - 6.2%) for all years. 
 Past 12 month marijuana use showed a clear pattern of increase since 2009 among the 
NMPR-X group, with 2005 estimates of 8.5% (SE = 0.2), 2009 estimates of 9.3% (SE = 0.2), 
and 2014 estimates of 11.9% (SE = 0.2). While past 12 month marijuana use was substantially 
more common in the NMPR-O (range: 68.4% to 79.7%) and NMPR-N (range: 44.2% to 50.3%) 
groups, no clear trends from year to year were found.  
 Although ever having injected a drug was more common reported among NMPR-O users 
(range: 15.0% to 27.2%) for all years than both the NMPR-N (range: 4.8% to 8.2%) and the 
NMPR-X (range: 1.1% to 1.3%) groups, the only significant year comparison was a drop seen 
when comparing 2013 (25.4%, SE = 3.5) to 2014 (15.0%, SE = 3.2).  
 Racial and ethnic diversity appeared to increase over time for all groups, with all 2005 to 
2014 comparisons being significant. The proportion of those reporting to be white, non-Hispanic 
dropped from 90.6% (SE = 1.4) to 77.5% (SE = 3.0) in the NMPR-O group, 71.4% (SE = 1.3) to 
61.6% (SE = 1.2) in the NMPR-N group, and 68.8% (SE=0.6) to 64.2% (SE=0.5) in the NMPR-
X group, from 2005 to 2014, respectively. Similarly, all groups appeared to show some trend of 
increases in age, with those reporting to be 50+ going from 4.8% (SE = 3.8) to 12.7% (SE = 4.3) 
in the NMPR-O group, 11.7% (SE = 1.6) to 20.3% (SE = 1.8) in the NMPR-N group, and 36.1% 
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(SE = 0.6) to 41.2% (SE = 0.4) in the NMPR-X group, when comparing 2005 to 2014, 
respectively. 
 No clear trends appear for the NMPR-O group, nor the NMPR-N group, in terms of sex, 
income, health insurance, and marital status. The NMPR-X group appears to show a pattern of 
increased income, with more individuals reporting being in the 75,000+ income category in 2014 
(34.9%, SE = 0.5) than in 2005 (28.5%, SE = 0.5); although, these values do not represent real 
income as they do not take into account inflation and therefore this pattern would be expected. 
Additionally, patterns in health insurance and marital status appeared in the NMPR-X groups, 
with having health insurance becoming more common (86.2%, SE = 0.3 in 2005 vs. 88.2%, SE = 
0.2 in 2014) and being married becoming less common (51.6%, SE = 0.4 in 2005 vs. 47.8%, SE 
= 0.4 in 2014), over time. 
 Table 4 provides unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) for 
recent heroin initiation and past 12 month heroin use by each independent variable, stratified by 
NMPR group.  
 Beginning with the recent heroin initiation analyses, when comparing odds of recent 
heroin initiation for different years, only unadjusted ORs for 2013 (OR = 2.58; 95% CI = 1.06, 
6.29) and 2014 (OR = 6.69; 95% CI = 3.08, 14.56) for the NMPR-N group were found to be 
significant, with survey respondents in 2013 and 2014 having greater odds of reporting recent 
heroin initiation than in the reference year of 2005.  
 Past 12 month heavy use of alcohol, use of marijuana, and use of cocaine were 
consistently associated with greater odds of recent heroin initiation for all NMPR groups, except 
for heavy alcohol use in the NMPR-O group. The ORs were the largest for NMPR-X group 
across all three substances, with ORs of 4.95 (95% CI = 3.03, 8.07), 39.51 (95% CI = 22.73, 
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68.67), and 70.22 (95% CI = 47.25, 104.36), for past 12 month heavy alcohol use, marijuana use, 
and cocaine use, respectively. Odds ratios for the NMPR-N group were 1.63 (95% CI = 1.09, 
2.44), 10.75 (95% CI = 6.14, 18.82), and 6.37 (95% CI = 4.25, 9.56), for the same variables, 
respectively; while the ORs for the NMPR-O group were smaller but significant for marijuana 
and cocaine use were 2.68 (95% CI = 1.57, 4.58) and 4.93 (95% CI = 3.51, 6.93), respectively, 
and  not significant for heavy alcohol use. 
  Additionally, ever having injected a drug was also a positive predictor of recent heroin 
initiation among all NMPR groups. Again, the NMPR-X group showed the largest ORs (OR = 
46.57; 95% CI = 30.39, 71.36), though the ORs for the NMPR-N (OR = 9.41; 95% CI = 6.26, 
14.12) and NMPR-O (OR = 2.52, 95% CI = 1.76, 3.61) groups were still substantial. 
 Black non-Hispanic race/ethnicity was associated with decreased odds of recent heroin 
initiation in the NMPR-O (OR = 0.15, 95% CI = 0.03, 0.64) and NMPR-X (OR = 0.11; 95% CI 
= 0.04, 0.34) groups, while male gender was a positive predictor in the NMPR-N (OR = 1.47; 
95% CI = 1.00, 2.17) and NMPR-X groups (OR = 2.33; 95% CI = 1.48, 3.66).  
 All income categories: 25,000-49,999 (OR = 0.47; 95% CI = 0.28, 0.79), 50,000-74,999 
(OR = 0.34; 95% CI = 0.19, 0.62), and 75,000+ (OR = 0.19; 95% CI = 0.11, 0.34), were 
associated with decreased odds of heroin initiation in the NMPR-X group when compared to the 
<25,000 reference category, while only the 75,000+ category (OR = 0.47; 95% CI = 0.25, 0.87)  
was associated with decreased odds in the NMPR-N group, and no associations were found in 
the NMPR-O group. 
 Several of the age categories were significant in each of the stratified groups, with the 
general pattern being for those that are significant to show decreased odds of recent heroin 
initiation relative to the reference category of ages 18-25. The significant ORs with the greatest 
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magnitude for the NMPR-O and NMPR-X groups were the comparisons between the 50+ group 
to the reference category, with ORs of 0.04 (95% CI = 0.01, 0.30) and 0.14 (95% CI = 0.03, 
0.60), respectively; while the comparison with the greatest magnitude in the NMPR-N group was 
the comparison of the 35-49 age group to the reference category (OR = 0.34; 95% CI = 0.17, 
0.66) 
 Health insurance was only found to have a significant odds ratio in the NMPR-X group, 
with those having health insurance having decreased odds of recent heroin initiation (OR = 0.37; 
95% CI = 0.24, 0.59).  Finally, those that were married were found to have decreased odds of 
recent heroin initiation in all groups, with ORs of 0.18 (95% CI = 0.08, 0.39), 0.18 (95% CI = 
0.09, 0.35), and 0.03 (95% CI = 0.01, 0.08), for the NMPR-O, NMPR-N, and NMPR-X groups, 
respectively.  
 Table 4 also provides the results for the unadjusted analyses for past 12 month heroin use 
as a dependent variable. For the NMPR-O group, respondents from 2011, 2012, and 2013 had 
greater odd of past 12 month heroin use, with ORs of 1.86 (95% CI = 1.04, 3.32), 2.04 (95% CI 
= 1.12, 3.69), and 1.99 (95% CI = 1.24, 3.17), respectively, when compared to the 2005 
reference group. Among the NMPR-N group, respondents from 2009 (OR = 1.96; 95% CI = 
1.01, 3.80), 2013 (OR = 2.41; 95% CI = 1.37, 4.25) and 2014 (OR = 4.54; 95% CI =2.62, 7.86) 
when compared to the reference year. In the NMPR-X group, unexpectedly, 2007 was associated 
with decreased odds of past 12 month heroin use (OR = 0.46; 95% CI = 0.23, 0.91). 
Additionally, 2014 was associated with greater odds of past 12 month heroin use (OR = 2.30; 
95% CI = 1.37, 3.85), among this group.  
 Past 12 month heavy alcohol use, marijuana use, cocaine use, and ever having injected 
any drugs showed similar results in the past 12 month heroin use analysis as the recent heroin 
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initiation analysis, with all consistently associated with greater odds of use, except heavy alcohol 
use in the NMPR-O group. 
 Interestingly, black non-Hispanic race/ethnicity was associated with greater odds (OR = 
2.00; 95% CI = 1.40, 2.85) of heroin use in the past 12 months among the NMPR-X group when 
compared to the white non-Hispanic reference group, which is in contrast to the decreased odds 
found  among the same group in the recent heroin initiation analysis.  Additionally, the all other 
race ethnicity category was found to have decreased odds of past 12 month heroin use (OR = 
0.50; 95% CI = 0.28, 0.90), when compared to the reference, in the NMPR-N group. No other 
associations for race/ethnicity were significant. 
 Most higher income groups were associated with decreased odds of past 12 month heroin 
use when compared to the less than $25,000 reference for all NMPR groups, while male sex was 
consistently associated with higher odds in each of the NMPR groups. The age category 12-17 
was consistently associated with decreased odds in all NMPR groups when compared to the 18-
25 age category, which is consistent with the recent heroin initiation findings. Interestingly, the 
26-34 age group was associated with greater odds of past 12 month heroin use in the NMPR-N 
group (OR = 1.40; 95% CI = 1.03, 1.90). Finally, both having health insurance and being 
married showed significantly lower odds of past 12 month heroin use among all NMPR groups. 
 Table 5 provides results from logistic regression modeling for each stratified groups of 
the two outcomes of interest, recent heroin initiation and past 12 month heroin use. Adjusted 
odds ratios and 95% confidence intervals are reported. 
 The relationship between year and each of the outcomes becomes more apparent after 
adjustment for covariates in both the NMPR-O and NMPR-N groups. In the NMPR-N group, 
2009 (OR = 2.63; 95% CI = 1.06, 6.52), 2011 (OR = 2.75; 95% CI = 1.14, 6.67), 2013 (OR = 
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2.72; 95% CI = 1.11, 6.66), and 2014 (OR = 2.29; 95% CI = 1.07, 4.92) were all associated with 
greater odds of recent heroin initiation, while 2013 was associated with the same in the NMPR-O 
group (OR = 2.29; 95% CI = 1.07, 4.92). No associations were found between year and recent 
heroin initiation in the NMPR-O group. 
 After adjustment for covariates, there was a more obvious pattern in the odds ratios 
between year and past 12 month heroin use in both the NMPR-O and NMPR-X groups, although 
contrary to the authors’ prediction, the pattern appeared to be similar in magnitude for the two 
groups. In the NMPR-O group 2010 (OR = 2.06; 95% CI = 1.16, 3.68), 2011 (OR = 2.86; 95% 
CI = 1.52, 5.39), 2012 (OR = 2.23; 95% CI = 1.26, 3.96), 2013 (OR = 2.52; 95% CI = 1.40, 
4.52), and 2014 (OR = 3.03; 95% CI = 1.65, 5.57), were associated with increased odds of past 
12 month heroin use. Similarly, 2009 (OR = 2.42; 95% CI = 1.26, 4.65), 2010 (OR = 2.21; 95% 
CI = 1.30, 3.74), 2011 (OR = 2.62; 95% CI = 1.35, 5.06), 2012 (OR = 1.98; 95% CI = 1.03, 
3.78), 2013 (OR = 2.60; 95% CI = 1.56, 4.32), and 2014 (OR = 5.80; 95% CI = 3.19, 10.52), 
were associated with increased odds in the NMPR-N group. Relationships between years and 
past 12 month heroin use did not significantly change after adjustment for the NMPR-X group. 
 In contrast to some of the unadjusted results, heavy alcohol was associated with 
decreased odds of both recent heroin initiation (OR = 0.64; 95% CI = 0.46, 0.89) and past 12 
month heroin use (OR = 0.64; 95% CI = 0.46, 0.88) in the NMPR-O group, and past 12 month 
heroin use in the NMPR-N (OR = 0.69; 95% CI = 0.47, 0.99) and NMPR-X (OR = 0.63; 95% CI 
= 0.40, 0.99) groups. Past 12 month marijuana use, cocaine use, and ever having injected a drug 
remained similar to the unadjusted results, showing consistently increased odds of recent heroin 
initiation and past 12 month heroin use, however many of the ORs were smaller in the adjusted 
analyses. 
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 Consistent with the unadjusted findings, black non-Hispanic race/ethnicity was associated 
with decreased odds (OR = 0.09; 0.03, 0.30) of recent heroin initiation and increased odds (OR = 
2.11; 95% CI = 1.39, 3.21) of past 12 month heroin use in the NMPR-X group. In the NMPR-N 
group, black non-Hispanic and Hispanic race/ethnicity were associated with increased odds of 
past 12 month heroin use, with ORs of 2.10 (95% CI = 1.26, 3.50) and 1.58 (95% CI = 1.00, 
2.48), respectively. 
 None of the income categories were significant for either outcome in the NMPR-O and 
NMPR-N groups. However, all of the income categories, 25,000-49,999 (OR = 0.65; 95% CI = 
0.46, 0.93), 50,000-74,999 (OR = 0.53; 95% CI = 0.35, 0.81), and 75,000+ (OR = 0.46; 95% CI 
= 0.30, 0.70), were associated with decreased odds of past 12 month heroin use in the NMPR-X 
group. Additionally, the 75,000+ group was associated with decreased odds of recent heroin 
initiation in the NMPR-X group as well (OR = 0.41; 95% CI = 0.22, 0.76). 
 The majority of the significant associations found in the unadjusted analyses for sex, age, 
and health insurance no longer remained in the logistic regression analyses. However, being 
married was still found to be consistently associated with decreased odds of recent heroin 
initiation and past 12 month heroin use in all groups in the adjusted analyses.  
 
DISCUSSION 
 The study indicated that past 12 month heroin use has increased in the both NMPR using 
subgroups in recent years. Additionally, heroin use was more common among the OxyContin 
users (NMPR-O) than the non-OxyContin using NMPR users (NMPR-N). However, contrary to 
the authors’ expectations, the strength of the relationship between year and heroin use was no 
more prominent in the NMPR-O group than the NMPR-N group, indicating growth in heroin use 
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may be similar in the two groups. Additionally, there was no obvious trend in past 12 month 
heroin use in the non-NMPR using population (NMPR-X). Finally, only the NMPR-N subgroup 
showed a pattern of increased recent heroin initiation in later years of the study. 
 The pattern of increased past 12 month heroin use across time is consistent with current 
literature investigating heroin use trends.61,68  One study of heroin use in the United States 
showed a growth of average annual rates of past year heroin use from 1.6 per 1,000 between 
2002 and 2004 to 2.6 per 1,000 between 2011 and 2013.61 It is also important to note that the 
growth in heroin use appeared to be primarily concentrated in NMPR users, supporting the 
notion presented by other literature that NMPR use frequently predates heroin use.26,29–31,68,69,74,75  
 One potential explanation for the increase in heroin use among NMPR users across time 
is that certain types of NMPR users may be being driven out of the NMPR using population at 
different rates. The recent growth of PDMPs and introduction of abuse-deterrent reformulations 
may be creating an environment in which certain users find it more difficult than others to obtain 
NMPRs and some may be more or less likely to continue using NMPRs. This is supported by 
literature associating the introduction of PDMPs with slowed growth in the supply of 
prescription drugs, and decreased NMPR treatment rates, prescription rates, and poison enter 
calls.28,34,39–44 Additionally, introduction of abuse-deterrent formulations have been associated 
with reductions in NMPR misuse, availability, and decreased reported associated fatalities.19–22 
These factors combined with increasing access to and decreasing cost of heroin may also create a 
“perfect storm” of sorts to that leads to increased heroin use, particularly among NMPR users. 
 To illustrate this point further, think of NMPR users in terms of frequency of NMPR use: 
frequent and infrequent, based on some number of days of use in the past 12 months. It could be 
that infrequent NMPR users are more likely to stop NMPR use when faced with increased 
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difficulty obtaining NMPRs than frequent users. Previous literature has shown that NMPR users 
that use NMPRs more frequently (greater number of total days used) are also more likely to use 
heroin in the past 12 months.31 If frequent NMPR users have greater odds of heroin use and 
infrequent NMPR users are becoming more likely to stop NMPR use in recent years, this would 
result in a greater concentration of frequent NMPR users in the NMPR using population and 
would result in greater frequency of past 12 month heroin use being reported as well. Additional 
research comparing heroin use over time across NMPR users stratified by frequency of NMPR 
use may provide insight into whether or not this explanation may be valid.  
 The lack of noticeable differences in association between year and heroin use in NMPR-
O users compared to NMPR-N users may indicate that the growing heroin epidemic is impacting 
NMPR users similarly regardless of type of NMPR used and may be less associated with 
individual policies than the change in the overall environment, policy and attitude in the U.S. 
toward prescription opioids. However, there may also be flaws in the design of the study that 
mask differences in particular types of NMPR users.  
 There have been several other types of abuse-deterrent formulations introduced recently 
in the market, including extended-release (ER) OxyContin, Embeda, ER Hysingla, ER Zohydro, 
and ER Targiniq, that target substances other than oxycodone to prevent misuse.48,50–52 
Interestingly, heroin use was much more common among OxyContin users than other NMPR 
users. It would be interesting to further stratify the NMPR-N group into groups of users based on 
some additional factors such as abuse potential of most frequently used NMPR, whether or not 
there is an abuse-deterrent version of the NMPR most commonly used, or some other factor that 
may influence increased heroin use. However, there would be significant difficulties in using the 
NSDUH to this effect. The OxyContin using subgroup was easily divided because the NSDUH 
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has an entire section devoted to the drug, treating it essentially as its own drug category. For 
other NMPRs, respondents are only asked which ones they have used in the specified time. 
Questions on frequency of use are only asked for NMPRs as a whole for these drugs and 
therefore subdividing this group further would prove challenging and misclassification would be 
a major concern. For these reasons the study did not pursue the above described additional 
stratification. 
 The majority of non-opioid substances were shown to be positive predictors of heroin use 
in most cases. However, heavy alcohol use was associated with decreased odds of heroin use in 
all NMPR groups and decreased odds of recent heroin initiation in the NMPR-O group. A 
previous study showed an inverse relationship between alcohol use and heroin consumption 
among a groups of addicts presenting for treatment that were subsequently followed over time.81 
One explanation could be that NMPR that supplement their addiction with alcohol are less likely 
to find the need for heroin use and vice versa. Essentially, the two may function in a similar role 
in supplementing NMPR use, with users being more likely to use one or the other rather than 
both. Additionally, it could be that the types of NMPR users that use alcohol are inherently 
different than those NMPR users willing to use heroin. Heroin is typically considered a “harder” 
substance to abuse than NMPRs or alcohol, in addition to the fact that the latter can be obtained 
legally, while heroin cannot. 
 The lack of significant change in heroin use among non-NMPR users indicates that the 
NMPR epidemic and heroin epidemic are closely tied. It cannot be said from this study what the 
causes or influencing factors are, but it is abundantly clear that there is an overall opioid 
epidemic currently in the U.S. and policy development should take into consideration all opioid 
abuse and develop strategies for deterring illicit use of these substances together. 
  




 The cross-sectional design of the survey used in the study prevents temporal conclusions 
from being made. This is a limitation in that the study is attempting to look at time trends of 
heroin use among NMPR subgroups and panel data would be superior in investigating these 
trends. However, the NSDUH is designed to be a nationally representative survey and therefore 
comparing use of heroin in the population from year to year does at least give insight as to 
whether or not heroin use is becoming more common among the populations of interest, even if 
we cannot say who is entering and exiting the population.  
 It must be noted that there are no state-level variables provided in the NSDUH public use 
files. PDMP policies vary significantly across states in terms of implementation and 
requirements. Additionally, state-level factors also likely influence drug use behavior. The study 
cannot account for any state-level variation. Also, both heroin use outcomes are rare in many of 
the stratified groups. This is especially an issue for recent heroin initiation in the NMPR-O group 
because it has a much smaller overall sample size than the other stratified groups. The sample 
size for the NMPR-O group may not be large enough to give an accurate depiction of recent 
heroin initiation in this group and therefore estimates should be interpreted with caution.  
 Finally, the study cannot directly associate the results with prescription opioid policies; 
there are many other factors that could be influencing the composition and drug use behavior of 
the opioid using population. It could be that access to heroin has happened to increase at the 
same time of these policies or that the market for heroin grew as restrictions on prescription 
opioids increased and drug dealers ceased this opportunity to make profit. The study cannot 
determine how these factors influenced users of prescription opioids and heroin in various 
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populations, however, the findings do suggest that they may have some kind of impact and 
further investigation into the subject may prove worthwhile. 
 
Conclusion 
 Future analyses should further stratify prescription opioid type used in the NMPR-N 
group based on potency, abuse potential, and research indicating which prescription opioids are 
being abused most often and route of intake. Additionally, further analyses of different groupings 
of user types such as heavy, moderate, and lights, may also be beneficial and provide insight into 
the characteristics of those using prescription opioids frequently. Finally, further research 
exploring the history and growth of the heroin and prescription opioid epidemics may further 
explain how these two epidemics grew simultaneously and how they have and do influence each 
other. Research of this type would give insight into the impact different drug markets have on 
each other and how those engaging in these markets respond to changes in supply and demand.  
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CHAPTER V: PUBLIC HEALTH AND POLICY IMPLICATIONS 
 
 The three papers presented in Chapters II, III, and IV provide evidence to support the 
notion that opioid policy and opioid use have changed in many ways over the past decade and 
these two factors may be associated with each other. Recent prescription opioid targeting policies 
been shown to be associated with several improved non-medical prescription opioid use related 
outcomes. These include slowed growth in prescription drug supply; decreased treatment rates, 
prescription rates and poison center calls; decreases in both non-oral and oral misuse of the 
targeted prescription opioid; and decreases in reported fatalities.19–22,28,34,39–45 However, previous 
studies and the results of the analyses indicate that some of these policies may be associated with 
the rise in heroin use.26,29–31 
 Policies and interventions related to prescription opioids have heavily focused on 
reducing access to prescription opioids. The majority of heroin associated policies have focused 
on other factors such as reducing the risk of spreading disease through needle exchange 
programs and reducing the risk of death when an overdose occurs through improving access to 
naloxone, a substance that can reverse the effects of an opioid overdose.82–90 Although, these 
policies do provide many benefits in terms of mitigating and preventing negative health 
outcomes associated with non-medical opioid use, one major problem is the non-medical 
prescription opioid epidemic and the heroin epidemic have largely been looked at separately by 
policy makers. It may be more beneficial for policy development to look at these two epidemics 
as one, i.e. a single opioid epidemic. 
 The policies targeting heroin, such as needle exchanges and increased naloxone access, 
likely benefit both heroin and non-medical prescription opioid users in that they can prevent 
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disease spread in all needle using opioid users and naloxone can reverse an overdose of 
prescription opioids in the same way it can reverse the effects in heroin users. However, the 
prescription opioid targeted policies such as prescription drug monitoring programs (PDMPs) 
and abuse-deterrent formulations, do not factor in heroin access, which may lead to increased 
heroin use among non-medical prescription opioid users. Development of policies that target 
heroin access in conjunction with these policies may lead to better health outcomes over the past 
decade; however, policies decreasing access to heroin are likely to prove much more difficult to 
develop given that the heroin market is an entirely illicit one. It is also important to note that 
medication assisted treatments, such as access methadone and buprenorphine, also benefit both 
types of non-medical opioid users similarly.91–96 
 There have been at least some policies developed to reduce access to and use of heroin, 
primarily ones focusing on increased criminal punishment for heroin trafficking.97 Additional 
policies that target heroin access in other ways, though, are likely needed given that the illicit 
heroin market has grown in recent years even with severe trafficking laws in place. Cultivation 
of the plant Papaver somniferum, a.k.a. the opium poppy, which is used to make heroin, is not 
common in the U.S.98,99 The majority of the heroin used in the United State comes from other 
countries, primarily Mexico and Columbia.98,99 This implies that in order to reduce access to 
heroin in the United States, international cooperation and coordination between countries from 
which heroin is coming into the U.S. may be necessary to reduce the heroin epidemic. Improved 
methods for detection of imports containing heroin and individuals entering the U.S. carrying 
heroin from these countries may also prove beneficial, although may not be realistic given 
potential costs of such policies. 
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 At least one study has been published arguing against the notion that the increase in 
prescription opioid policy is associated with the rise in heroin use, primarily arguing that the 
heroin epidemic began before many of these policies were enacted.100 However, the fact that the 
epidemic may have begun before many of the non-medical prescription opioid use policies were 
enacted does not mean that there is no association between the two. There may be an interactive 
effect in that the increased access to and decrease price of heroin in addition to the development 
of these policies resulted in the heroin together resulted in the heroin epidemic being larger than 
it would have been had one of the factors been absent. Given how recent many of these policies 
were developed, it may be many years before research can adequately answer whether or not this 
was the case. 
 Finally, there are several concerning recent developments in the opioid epidemic that will 
certainly need to be addressed quickly. New and more dangerous substances are being 
introduced to the illicit opioid market; examples include fentanyl and “krokodil”.101,102 Fentanyl 
is a highly potent opioid, 30-50 times more so than heroin, and there has been a recent surge in 
overdoses associated with heroin laced fentanyl.101 Additionally, “krokodil”, the street name for 
a home-made injectable substance that is a cheap alternative to heroin has begun to be introduced 
into the heroin market.102 The homemade process used to make krokodil has been shown to 
include agents that result in ulcerations, gangrene, and necrosis, and leading to limb amputation 
and death.102,103 Although, krokodil has been shown not to have significantly penetrated the U.S. 
illicit opioid market, the health consequences associated with it are severe and it is a potential 
risk that should be monitored.104 These recent introductions show that the illicit opioid market is 
an evolving one and can adapt to targeted policy. Public health officials and policy developers 
will have to be vigilant and adaptive in order to combat this ever evolving epidemic.  
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TABLES 
Table 1. Demographic characteristics of past 12 month non-medical pain reliever users 
  
2005-2006 2007-2008 2009-2010 2011-2012 2013-2014 
N = 8,620 N = 8,551 N = 8,415 N = 7,633 N = 5,871 
% SE % SE % SE % SE % SE 
Residence                     
  Metro - - 83.9 0.7 84.5 0.7 85.8 0.8 74.8 0.9 
  Non-Metro - - 16.1 0.7 15.5 0.7 14.2 0.8 15.2 0.9 
Race/Ethnicity                     
  White Non-Hispanic 73.2 1.0 73.9 0.8 72.0 0.9 67.6 1.0 65.1 1.0 
  Black Non-Hispanic 8.8 0.6 9.6 0.6 8.9 0.5 11.0 0.8 11.9 0.7 
  Hispanic 13.5 0.8 11.5 0.7 13.6 0.8 16.3 0.8 16.7 0.8 
  All Other 4.5 0.4 5.0 0.5 5.6 0.7 5.1 0.4 6.3 0.5 
Highest Education                     
  Less than H.S. 17.7 0.8 15.9 0.7 15.5 0.7 16.1 0.7 15.8 0.8 
  H.S. 27.8 0.8 29.0 0.9 27.8 0.9 28.3 1.0 26.9 1.0 
  College 39.8 0.9 41.9 1.2 44.0 1.1 43.5 0.8 46.4 1.1 
  12-17 years old 14.8 0.4 13.2 0.4 12.8 0.4 12.1 0.4 10.8 0.4 
Income                     
  <20,000 24.9 0.7 22.6 0.7 24.5 0.9 24.7 0.9 25.6 0.9 
  20,000-49,999 35.6 0.9 35.0 1.2 34.9 1.1 36.0 1.0 33.1 1.1 
  50,000-74,999 16.2 0.7 17.1 0.8 14.6 0.7 15.3 0.7 16.0 0.8 
  75,000+ 23.3 0.9 25.3 0.9 26.0 1.1 24.0 1.0 25.3 0.9 
Sex                     
  Male 55.2 1.0 55.4 0.9 56.8 0.9 54.5 1.3 53.5 1.1 
  Female 44.8 1.0 44.7 0.9 43.2 0.9 45.5 1.3 46.5 1.1 
Age                     
  12-17 14.8 0.4 13.2 0.4 12.8 0.4 12.1 0.4 10.8 0.4 
  18-25 33.7 0.9 32.8 0.8 31.2 0.9 28.7 0.9 26.9 0.8 
  26-34 19.7 0.7 19.3 0.9 21.9 0.9 23.1 1.0 23.2 1.0 
  35-49 22.1 0.9 23.6 0.9 21.0 1.0 21.5 1.1 21.4 0.9 
  50+ 9.8 1.0 11.1 1.1 13.2 1.0 14.5 1.1 17.6 1.2 
Health Insurance                     
  Yes 76.0 0.8 75.1 0.7 74.7 0.8 75.2 1.0 77.6 1.0 
  No 24.0 0.8 24.9 0.7 25.3 0.8 24.8 1.0 22.4 1.0 
Marital Status                     
  Married 27.6 1.3 29.0 1.0 26.3 1.3 28.1 1.1 28.3 1.2 
  Not Married 72.4 1.3 71.0 1.0 73.7 1.3 71.9 1.1 71.7 1.2 
 
    = p<0.05 for comparison to 2005-2006 year group category 
  
    = p<0.05 for comparison to previous year group category 
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Table 2. Drug use among past 12 month non-medical pain reliever users 
  
2005-2006 2007-2008 2009-2010 2011-2012 2013-2014 
N = 8,620 N = 8,551 N = 8,415 N = 7,633 N = 5,871 
% SE % SE % SE % SE % SE 
NMPR Use Last 12 
Months                     
  1-29 Days 66.0 1.0 64.4 0.9 62.7 1.2 62.1 1.0 59.2 1.1 
  30-89 Days 18.8 0.8 19.2 0.7 18.9 1.0 19.7 0.7 20.9 0.9 
  90+ Days 15.2 0.8 16.2 0.7 18.5 0.9 18.1 0.8 19.8 0.9 
OxyContin Use Last 12 M                     
  None 89.5 0.6 88.3 0.6 85.5 0.7 86.6 0.8 87.7 0.7 
  1-29 Days 7.5 0.5 7.8 0.4 9.7 0.5 8.3 0.7 7.9 0.5 
  30-89 Days 1.6 0.2 2.0 0.3 2.3 0.2 2.1 0.3 1.9 0.3 
  90+ Days 1.3 0.2 1.9 0.3 2.5 0.3 3.0 0.3 2.5 0.3 
Heroin Use Last 12 M                     
  None 97.5 0.3 97.4 0.3 96.3 0.4 96 0.4 94.6 0.4 
  1-29 Days 1.2 0.2 1.2 0.2 1.7 0.2 1.7 0.2 2.4 0.3 
  30-89 Days 0.2 0.1 0.4 0.1 0.9 0.2 0.6 0.1 0.7 0.1 
  90+ Days 1.1 0.3 0.9 0.1 1.1 0.2 1.7 0.2 2.2 0.3 
Alcohol Use Last 12 M                     
  None 13.3 0.8 13.2 0.6 13.3 0.8 14.5 0.9 16.2 0.8 
  1-29 Days 22.6 0.8 21.9 0.7 22.6 0.8 24.6 0.9 22.3 0.8 
  30-89 Days 21.4 0.8 21.8 0.8 21.4 0.8 21.5 0.8 22.6 0.9 
  90+ Days 42.7 0.9 43.1 0.9 42.7 0.9 39.4 1.1 39.0 1.0 
Cocaine Use Last 12 M                     
  None 79.8 0.6 81.2 0.7 84.0 0.6 84.9 0.5 84 0.8 
  1-29 Days 12.6 0.6 13.3 0.6 11.4 0.5 10.3 0.4 11.1 0.6 
  30-89 Days 3.6 0.3 2.6 0.3 2.4 0.3 2.5 0.3 2.7 0.3 
  90+ Days 4.0 0.4 2.9 0.3 2.2 0.3 2.3 0.3 2.2 0.3 
Crack Use Last 12 M                     
  None 95.0 0.4 95.9 0.3 96.3 0.4 96.9 0.4 97.3 0.3 
  1-29 Days 3.0 0.3 2.4 0.2 2.0 0.3 1.8 0.2 1.2 0.2 
  30-89 Days 1.2 0.2 0.7 0.1 0.6 0.2 0.5 0.2 0.5 0.1 
  90+ Days 0.8 0.2 1.1 0.2 1.0 0.2 0.8 0.2 1.0 0.2 
                          
    = p<0.05 for comparison to 2005-2006 year group category 
               
    = p<0.05 for comparison to previous year group category, i.e. 2013-2014 vs. 2011-2012 
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Table 2 Continued. Drug use among past 12 month non-medical pain reliever users 
  
2005-2006 2007-2008 2009-2010 2011-2012 2013-2014 
N = 8,620 N = 8,551 N = 8,415 N = 7,633 N = 5,871 
% SE % SE % SE % SE % SE 
Stimulant Use Last 12 M                     
  None 87.8 0.5 88.8 0.5 88.5 0.5 89.3 0.6 87.7 0.7 
  1-29 Days 7.1 0.4 6.3 0.4 6.3 0.4 6.1 0.5 6.2 0.4 
  30-89 Days 2.1 0.3 2.3 0.3 2.8 0.3 2.1 0.3 2.9 0.5 
  90+ Days 3.0 0.4 2.6 0.3 2.5 0.3 2.5 0.3 3.2 0.3 
Marijuana Use Last 12 M                     
  None 51.6 0.9 51.7 1.0 48.8 1.0 48.8 1.2 49.3 1.1 
  1-29 Days 16.7 0.7 16.1 0.7 15.7 0.6 15.1 0.7 14.6 0.8 
  30-89 Days 7.7 0.5 7.6 0.4 8.0 0.6 7.8 0.5 7.6 0.6 
  90+ Days 24.0 0.6 24.5 0.7 27.4 0.9 28.3 1.1 28.5 0.9 
Sedative Use Last 12 M                     
  None 96.4 0.4 96.9 0.3 96.0 0.4 97.8 0.3 96.9 0.4 
  1-29 Days 2.2 0.2 1.8 0.2 2.1 0.3 1.3 0.2 1.8 0.3 
  30-89 Days 0.7 0.2 0.4 0.1 1.1 0.2 0.4 0.1 0.6 0.1 
  90+ Days 0.7 0.2 0.9 0.2 0.7 0.2 0.5 0.1 0.7 0.2 
Tranquilizer Use Last 12 M                     
  None 72.8 0.7 74.3 0.7 72.6 0.9 71.4 0.9 73.8 1.0 
  1-29 Days 17.4 0.7 16.6 0.6 17.0 0.8 17.9 0.8 16.1 0.8 
  30-89 Days 5.4 0.4 5.0 0.4 5.6 0.4 6.1 0.4 5.2 0.4 
  90+ Days 4.4 0.3 4.1 0.4 4.8 0.4 4.6 0.4 5.1 0.6 
Hallucinate Use Last 12 M                     
  None 84.5 0.6 84.6 0.5 84.0 0.5 85.0 0.5 85.9 0.7 
  1-29 Days 12.7 0.5 12.9 0.5 13.6 0.5 12.4 0.5 12.3 0.6 
  30-89 Days 1.9 0.2 1.8 0.2 1.7 0.2 1.8 0.2 1.2 0.2 
  90+ Days 0.9 0.1 0.7 0.1 0.7 0.1 0.7 0.2 0.6 0.1 
Inhalant Use Last 12 M                     
  None 93.6 0.4 93.6 0.4 93.8 0.4 94.7 0.5 95.9 0.3 
  1-29 Days 5.0 0.3 4.8 0.3 4.8 0.4 3.8 0.4 3.4 0.3 
  30-89 Days 0.7 0.1 0.9 0.1 0.7 0.1 1.0 0.3 0.5 0.1 
  90+ Days 0.6 0.1 0.6 0.1 0.8 0.3 0.5 0.1 0.2 0.1 
Injection Drug Use Ever                     
  Yes 6.9 0.5 7.6 0.6 8.3 0.6 8.8 0.7 9.4 0.6 
  No 93.1 0.5 92.4 0.6 91.7 0.6 91.2 0.7 90.5 0.6 
                          
    = p<0.05 for comparison to 2005-2006 year group category 
               
    = p<0.05 for comparison to previous year group category, i.e. 2013-2014 vs. 2011-2012 
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Table 3. Sample Characteristics by Non-Medical Pain Reliever (NMPR) Use and Year 
  
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
N = 55,905 N = 55,279 N = 55,435 N = 55,110 N = 55,234 N = 57,313 N = 58,397 N = 55,268 N = 55,160 N = 55,271 
Sample Size                     
  NMPR OxyContin Users (N) 593 551 616 634 747 742 643 538 429 368 
  Non-OxyContin  NMPR Users (N) 3,746 3,730 3,663 3,638 3,595 3,331 3,317 3,135 2,745 2,329 
  NMPR Non-Users (N) 51,566 50,998 51,156 50,838 50,892 53,240 54,437 51,595 51,986 52,574 
Variable % SE % SE % SE % SE % SE % SE % SE % SE % SE % SE 
Recent Heroin Initiation                                         
  
Non-Medical OxyContin Users 
(NMPR-O) 
4.7 1.1 3.2 0.7 4.1 1.4 3.5 0.8 4.2 0.8 5.2 1.1 5.2 1.1 5.7 1.2 7.8 2.2 3.9 1.0 
  
Non-OxyContin NMPR Users  
(NMPR-N) 
0.3 0.1 0.5 0.1 0.5 0.1 0.2 0.1 0.8 0.2 0.9 0.5 0.8 0.2 0.6 0.1 0.9 0.3 2.2 0.5 
  No NMPR Use (NMPR-X) 0.02 0.01 0.02 0.01 0.01 0.00 0.03 0.01 0.02 0.01 0.01 0.00 0.02 0.01 0.01 0.00 0.02 0.00 0.04 0.01 
Heroin Use in Past 12 Months                                       
  NMPR-O 10.0 1.7 11.4 3.2 11.2 2.5 11.3 2.1 13.8 1.9 13.4 2.1 17.1 2.9 18.4 3.2 18.1 2.7 15.6 2.8 
  NMPR-N 1.1 0.3 2.0 0.6 1.3 0.3 1.6 0.4 2.2 0.5 1.8 0.4 1.9 0.4 1.9 0.4 2.7 0.4 4.9 0.7 
  NMPR-X 0.06 0.01 0.08 0.02 0.03 0.01 0.06 0.02 0.08 0.02 0.08 0.02 0.08 0.02 0.07 0.02 0.06 0.01 0.14 0.02 
Heavy Alcohol Use Past 12 Months                                
  NMPR-O 41.0 3.4 31.4 3.1 32.4 3.1 30.5 3.0 33.1 2.7 31.3 2.8 31.5 3.2 24.3 3.5 24.8 3.0 26.9 3.9 
  NMPR-N 22.9 1.2 22.6 0.9 21.7 1.1 24.3 1.3 22.2 1.2 22.4 1.3 19.5 1.3 19.0 1.1 19.4 1.7 18.0 1.0 
  NMPR-X 5.6 0.2 6.0 0.2 5.9 0.2 6.2 0.2 6.0 0.2 5.8 0.2 5.5 0.2 5.8 0.2 5.7 0.2 5.6 0.2 
Marijuana Use Past 12 Months                                         
  NMPR-O 74.4 3.6 75.1 2.8 73.3 3.9 76.4 3.1 79.7 2.5 75.1 2.6 76.8 3.4 74.2 3.9 68.4 4.2 69.9 3.3 
  NMPR-N 45.5 1.5 45.2 1.4 45.6 1.4 44.2 1.4 48.2 1.8 45.5 1.5 49.2 1.5 45.9 1.8 50.3 1.7 46.8 1.5 
  NMPR-X 8.5 0.2 8.3 0.2 8.1 0.2 8.4 0.2 9.3 0.2 9.7 0.2 9.6 0.2 10.3 0.2 10.8 0.2 11.9 0.2 
                                              
    Significantly different from 2005 at the α=0.05 level 
                         
    Significantly different from previous year at the α=0.05 level 
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Table 3 Continued. Sample Characteristics by Non-Medical Pain Reliever (NMPR) Use and Year 
Variable 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
% SE % SE % SE % SE % SE % SE % SE % SE % SE % SE 
Cocaine Use Past 12 Months                                
  NMPR-O 45.4 3.4 44.4 3.1 47.2 3.9 43.4 3.7 37.2 3.0 37.8 3.1 32.8 2.6 35.9 3.4 29.4 3.4 32.8 3.5 
  NMPR-N 17.2 1.0 17.7 1.1 15.2 1.1 15.7 1.0 13.6 0.9 11.0 0.9 10.7 0.9 13.3 0.9 14.7 1.3 13.1 1.0 
  NMPR-X 1.3 0.1 1.5 0.1 1.5 0.1 1.3 0.1 1.2 0.1 1.1 0.1 0.9 0.1 1.1 0.1 1.0 0.1 1.2 0.1 
Injection Drug Use Ever                                       
  NMPR-O 20.3 2.4 17.8 3.6 20.2 3.8 25.1 4.1 22.7 3.2 17.9 2.5 20.4 2.6 27.2 4.5 25.4 3.5 15.0 3.2 
  NMPR-N 5.6 0.8 5.4 0.7 6.3 1.0 4.8 0.7 6.6 1.0 6.0 0.9 5.9 0.8 7.1 1.0 8.2 1.0 7.6 0.8 
  NMPR-X 1.2 0.1 1.3 0.1 1.2 0.1 1.3 0.1 1.1 0.1 1.1 0.1 1.1 0.1 1.1 0.1 1.3 0.1 1.3 0.1 
Race/Ethnicity                                
  NMPR-O                                
   White Non-Hispanic 90.6 1.4 89.1 3.0 84.0 3.4 89.0 1.6 85.2 1.7 83.4 2.2 81.6 2.5 80.3 3.0 84.1 3.6 77.5 3.0 
   Black Non-Hispanic 0.7 0.2 2.2 1.2 6.8 3.1 3.4 1.4 3.6 1.0 4.6 1.2 6.1 1.5 4.4 1.6 3.4 1.7 5.9 1.7 
   Hispanic 5.4 1.4 7.2 2.9 4.7 1.3 4.4 1.1 8.2 1.4 6.0 1.4 8.7 1.9 10.0 2.1 9.5 2.7 10.1 2.0 
   All Other 3.3 0.8 1.6 0.6 4.6 1.6 3.3 0.7 3.0 0.8 5.4 1.5 3.6 0.8 5.5 1.2 3.0 0.7 6.5 1.6 
  NMPR-N                                
   White Non-Hispanic 71.4 1.3 71.2 1.6 71.9 1.6 72.4 1.0 72.4 1.3 67.3 1.4 67.6 1.6 63.7 1.7 64.0 1.7 61.6 1.2 
   Black Non-Hispanic 10.2 0.9 9.1 0.9 10.0 0.9 10.5 0.8 9.5 0.9 9.9 1.0 10.0 0.8 13.6 1.3 11.0 1.1 15.0 1.0 
   Hispanic 13.9 1.2 14.8 1.1 13.2 1.1 11.7 0.9 12.8 1.0 16.7 1.3 17.2 1.4 17.5 1.4 17.9 1.5 17.4 1.0 
   All Other 4.6 0.7 4.9 0.6 4.9 0.6 5.4 0.7 5.3 0.8 6.2 1.2 5.3 0.7 5.2 0.7 7.1 0.9 6.0 0.8 
  NMPR-X                                
   White Non-Hispanic 68.8 0.6 68.2 0.6 67.9 0.5 67.5 0.5 67.1 0.5 66.9 0.4 65.5 0.5 65.2 0.5 64.7 0.5 64.2 0.5 
   Black Non-Hispanic 11.9 0.3 12.0 0.3 11.9 0.4 11.9 0.3 12.1 0.3 12.1 0.3 11.9 0.3 11.8 0.4 12.0 0.4 11.9 0.3 
   Hispanic 13.2 0.4 16.6 0.4 13.9 0.4 14.2 0.3 14.4 0.4 14.5 0.3 15.3 0.4 15.4 0.4 15.7 0.3 16.0 0.4 
    All Other 6.1 0.3 6.2 0.3 6.2 0.2 6.4 0.2 6.4 0.3 6.6 0.3 7.4 0.3 7.6 0.3 7.6 0.3 8.0 0.3 
                                              
    Significantly different from 2005 at the α=0.05 level 
                         
    Significantly different from previous year at the α=0.05 level 
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Table 3 Continued. Sample Characteristics by Non-Medical Pain Reliever (NMPR) Use and Year 
Variable 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
% SE % SE % SE % SE % SE % SE % SE % SE % SE % SE 
Sex (% Male)                                     
  NMPR-O 59.0 3.8 55.5 4.2 58.2 3.9 60.6 3.1 61.4 3.1 56.8 3.1 61.1 2.8 62.0 2.8 65.6 3.3 56.5 3.3 
  NMPR-N 52.8 1.5 57.1 1.4 55.4 1.1 54.2 1.5 55.2 1.3 57.8 1.7 52.9 1.8 53.9 2.0 51.1 1.9 53.7 1.3 
  NMPR-X 48.2 0.5 48.1 0.4 48.1 0.4 48.2 0.5 48.2 0.4 48.2 0.5 48.1 0.4 48.1 0.4 48.2 0.4 48.2 0.3 
Age                                
  NMPR-O                                
   12-17 15.4 1.7 16.2 1.8 15.6 1.6 15.0 1.6 13.9 1.5 12.9 1.4 13.9 1.6 11.6 1.5 9.9 1.2 14.0 1.6 
   18-25 45.4 3.1 45.1 3.5 40.4 3.7 40.4 3.3 45.9 2.9 39.9 2.8 37.7 2.9 37.2 2.9 33.0 3.8 32.2 3.3 
   26-34 19.1 2.9 14.4 2.3 19.3 3.5 22.9 3.4 19.6 2.9 24.4 3.3 25.0 2.9 23.0 3.4 26.6 3.7 23.8 3.3 
   35+ 15.3 3.0 16.6 3.3 15.2 3.1 18.2 4.3 11.9 2.6 16.7 2.7 16.1 2.8 14.0 2.9 17.0 3.1 17.3 3.0 
   50+ 4.8 3.8 7.7 3.7 9.4 3.9 3.5 1.6 8.8 2.7 6.0 2.5 7.3 3.1 14.2 4.4 13.5 4.4 12.7 4.3 
  NMPR-N                                         
   12-17 14.8 0.7 14.5 0.5 13.0 0.6 12.8 0.6 13.2 0.7 12.1 0.6 13.8 0.7 10.4 0.6 10.1 0.6 11.3 0.6 
   18-25 33.2 1.0 31.5 1.2 31.5 1.1 32.1 1.2 29.9 1.1 28.5 1.1 28.7 1.2 26.2 1.3 27.3 1.2 24.9 1.1 
   26-34 19.4 1.1 20.6 1.2 18.7 1.2 19.5 1.1 21.0 1.1 22.7 1.6 23.7 1.4 22.4 1.6 23.9 1.9 21.9 1.2 
   35-49 20.9 1.4 24.5 1.2 24.8 1.4 24.1 1.4 22.2 1.4 22.1 1.4 21.2 1.8 23.7 1.4 22.5 1.6 21.6 1.2 
   50+ 11.7 1.6 8.9 1.2 12.0 1.6 11.5 1.5 13.7 1.6 14.7 1.6 12.6 1.8 17.3 1.9 16.3 2.0 20.3 1.8 
  NMPR-X                                
   12-17 10.2 0.2 10.1 0.1 10.0 0.1 9.8 0.1 9.6 0.1 9.5 0.1 9.5 0.1 9.5 0.1 9.5 0.1 9.3 0.1 
   18-25 12.3 0.2 12.3 0.2 12.2 0.2 12.2 0.2 12.4 0.2 12.6 0.2 12.6 0.2 12.6 0.2 12.6 0.2 12.7 0.2 
   26-34 14.1 0.2 14.0 0.2 14.0 0.3 14.0 0.3 14.0 0.3 14.0 0.3 13.7 0.3 13.8 0.3 13.8 0.3 14.0 0.2 
   35-49 27.3 0.4 26.5 0.4 26.5 0.4 26.0 0.3 25.7 0.4 24.9 0.3 24.0 0.3 23.5 0.4 23.2 0.4 22.8 0.3 
    50+ 36.1 0.6 37.2 0.5 37.3 0.6 38.1 0.5 38.4 0.5 39.1 0.5 40.3 0.5 40.7 0.5 40.9 0.5 41.2 0.4 
                                              
    Significantly different from 2005 at the α=0.05 level 
                         
    Significantly different from previous year at the α=0.05 level 
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Table 3 Continued. Sample Characteristics by Non-Medical Pain Reliever (NMPR) Use and Year 
Variable 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
% SE % SE % SE % SE % SE % SE % SE % SE % SE % SE 
Income                                 
  NMPR-O                                
   <25,000 26.4 3.0 28.5 3.4 22.0 2.5 21.9 2.0 30.4 3.6 24.5 2.7 19.3 2.1 27.5 2.9 27.5 3.7 25.3 2.7 
   25,000-49,999 33.9 3.2 31.7 3.1 32.1 3.6 36.6 3.6 33.6 3.6 37.9 2.6 36.6 3.0 37.7 3.8 27.1 3.8 33.2 2.8 
   50,000-75,000 15.4 2.2 13.7 2.3 18.0 2.9 12.6 2.2 12.6 1.9 10.5 1.7 18.3 2.8 11.1 1.7 18.1 3.9 15.1 3.3 
   75,000+ 24.3 3.5 26.1 3.4 27.9 3.1 28.8 3.6 23.4 2.4 27.1 3.0 25.8 2.9 23.7 4.0 27.3 3.1 26.4 3.5 
  NMPR-N                                
   <25,000 24.9 1.1 24.2 1.0 24.2 1.2 21.2 1.0 24.0 1.2 24.0 1.5 26.1 1.4 23.8 1.4 25.4 1.3 25.5 1.3 
   25,000-49,999 37.8 1.3 34.2 1.4 36.2 1.5 34.0 1.7 33.9 1.5 35.5 1.6 37.7 1.7 34.3 1.4 34.1 1.9 33.0 1.4 
   50,000-75,000 14.7 1.1 17.9 1.0 15.8 1.0 18.8 1.2 14.2 1.1 16.1 1.1 16.1 1.3 14.8 1.0 15.3 1.3 16.5 1.0 
   75,000+ 22.5 1.5 23.6 1.3 23.7 1.2 26.1 1.5 27.9 1.7 24.3 1.2 20.1 1.4 27.1 1.5 25.2 1.6 25.0 1.2 
  NMPR-X                                
   <25,000 18.7 0.4 18.8 0.4 17.8 0.4 16.6 0.3 17.1 0.4 18.3 0.4 18.9 0.4 18.6 0.3 18.0 0.4 17.8 0.3 
   25,000-49,999 34.4 0.5 34.5 0.4 32.7 0.5 32.3 0.4 32.5 0.4 33.2 0.5 32.2 0.3 32.5 0.5 31.2 0.4 30.7 0.4 
   50,000-75,000 18.4 0.3 17.6 0.2 18.4 0.4 18.5 0.3 17.4 0.3 17.0 0.3 17.1 0.3 16.7 0.3 17.2 0.4 16.5 0.3 
    75,000+ 28.5 0.5 29.1 0.4 31.1 0.7 32.6 0.5 33.0 0.6 31.5 0.6 31.9 0.5 32.2 0.5 33.6 0.6 34.9 0.5 
Married                                
  NMPR-O 15.1 3.1 11.6 3.0 19.7 4.8 21.7 4.4 9.6 1.9 14.6 2.5 18.3 3.0 24.3 4.5 19.4 4.2 19.3 3.5 
  NMPR-N 29.0 1.7 29.5 1.7 29.6 1.5 30.6 1.8 29.7 1.8 27.6 1.8 26.8 1.5 31.2 2.0 30.0 1.9 29.2 1.7 
  NMPR-X 51.6 0.4 50.9 0.4 50.9 0.4 50.6 0.4 50.4 0.5 48.7 0.5 48.8 0.5 48.5 0.5 48.0 0.4 47.8 0.4 
Health Insurance                                         
  NMPR-O 68.8 3.2 66.5 3.9 76.8 2.5 64.8 4.2 63.1 3.6 71.2 2.8 72.8 3.1 72.0 3.4 72.9 4.2 77.1 3.3 
  NMPR-N 78.1 1.3 75.9 1.1 74.5 1.2 76.8 1.3 75.9 1.1 75.9 1.5 74.7 1.6 76.4 1.5 75.4 1.7 79.7 1.2 
  NMPR-X 86.2 0.3 85.8 0.2 85.7 0.4 85.9 0.3 85.2 0.3 84.3 0.3 84.8 0.3 85.0 0.3 85.3 0.3 88.2 0.2 
                                              
    Significantly different from 2005 at the α=0.05 level 
                         
    Significantly different from previous year at the α=0.05 level 
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Table 4. Unadjusted ORs and 95% Cls for Heroin Initiation in Past 12 Months and Heroin Use in Past 12 Months  Independent Variables Stratified by Non-Medical Pain Reliever (NMPR) User Type  
Variable 










No NMPR Use 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Year                                     
  2005 REF - - REF - - REF - - REF - - REF - - REF - - 
  2006 0.67 0.33 1.37 1.53 0.64 3.66 1.00 0.45 2.27 1.16 0.54 2.52 1.82 0.76 4.34 1.30 0.71 2.37 
  2007 0.87 0.40 1.90 1.57 0.65 3.79 0.45 0.18 1.14 1.14 0.62 2.09 1.18 0.57 2.46 0.46 0.23 0.91 
  2008 0.74 0.37 1.47 0.58 0.24 1.42 1.36 0.52 3.55 1.14 0.65 2.01 1.44 0.70 2.96 1.08 0.57 2.05 
  2009 0.88 0.47 1.68 2.23 0.93 5.33 1.05 0.40 2.71 1.44 0.90 2.33 1.96 1.01 3.80 1.29 0.69 2.42 
  2010 1.12 0.65 1.95 2.56 0.71 9.30 0.49 0.19 1.25 1.40 0.87 2.23 1.64 0.91 2.96 1.29 0.66 2.50 
  2011 1.12 0.54 2.32 2.30 0.97 5.43 0.94 0.35 2.55 1.86 1.04 3.32 1.71 0.89 3.31 1.32 0.70 2.48 
  2012 1.22 0.62 2.40 1.70 0.72 4.01 0.48 0.19 1.21 2.04 1.12 3.69 1.70 0.94 3.06 1.23 0.70 2.18 
  2013 1.73 0.82 3.63 2.58 1.06 6.29 0.74 0.34 1.63 1.99 1.24 3.17 2.41 1.37 4.25 0.92 0.56 1.54 
  2014 0.82 0.40 1.69 6.69 3.08 14.56 1.59 0.70 3.59 1.67 0.96 2.91 4.54 2.62 7.86 2.30 1.37 3.85 
Heavy Alcohol Use Past 12 M                                     
  Yes 0.96 0.72 1.30 1.63 1.09 2.44 4.95 3.03 8.07 0.92 0.70 1.21 1.62 1.17 2.24 3.48 2.50 4.84 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
Marijuana Use Past 12 Months                           
  Yes 2.68 1.57 4.58 10.75 6.14 18.82 39.51 22.73 68.67 2.45 1.80 3.34 3.89 2.68 5.66 14.72 10.69 20.27 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
Cocaine Use Past 12 Months                                     
  Yes 4.93 3.51 6.93 6.37 4.25 9.56 70.22 47.25 104.36 5.15 3.81 6.96 10.37 7.42 14.50 89.13 67.10 118.40 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
Injection Drug Use Ever                                     
  Yes 2.52 1.76 3.61 9.41 6.26 14.12 46.57 30.39 71.36 10.85 8.07 14.59 28.59 21.50 38.03 87.02 65.61 115.43 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
                                          
    Significant Odds Ratio at the α=0.05 level 
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Table 4 Continued. Unadjusted ORs and 95% Cls for Heroin Initiation in Past 12 Months and Heroin Use in Past 12 Months  Independent Variables Stratified by Non-Medical Pain Reliever 
(NMPR) User Type  
Variable 










No NMPR Use 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Race/Ethnicity                                     
  White Non-Hispanic REF - - REF - - REF - - REF - - REF - - REF - - 
  Black Non-Hispanic 0.15 0.03 0.64 0.47 0.17 1.31 0.11 0.04 0.34 0.58 0.23 1.48 1.02 0.64 1.62 2.00 1.40 2.85 
  Hispanic 0.65 0.37 1.15 0.57 0.32 1.00 1.04 0.58 1.84 1.16 0.63 2.12 0.98 0.61 1.56 1.48 0.96 2.27 
  All Other 0.98 0.48 2.01 0.67 0.31 1.45 0.62 0.27 1.45 0.63 0.35 1.15 0.50 0.28 0.90 0.80 0.43 1.51 
Sex                                     
  Male 1.19 0.86 1.63 1.47 1.00 2.17 2.33 1.48 3.66 1.91 1.53 2.38 1.94 1.44 2.61 1.82 1.32 2.50 
  Female REF - - REF - - REF - - REF - - REF - - REF - - 
Age                                     
  12-17 0.66 0.48 0.90 0.62 0.41 0.93 0.60 0.46 0.78 0.37 0.27 0.50 0.40 0.28 0.58 0.32 0.23 0.43 
  18-25 REF - - REF - - REF - - REF - - REF - - REF - - 
  26-34 0.80 0.52 1.23 0.63 0.38 1.05 0.65 0.46 0.90 1.29 0.95 1.74 1.40 1.03 1.90 0.96 0.68 1.34 
  35-49 0.23 0.09 0.56 0.34 0.17 0.66 0.24 0.14 0.41 0.76 0.50 1.16 0.77 0.54 1.10 0.54 0.39 0.74 
  50+ 0.04 0.01 0.30 0.25 0.05 1.18 0.14 0.03 0.60 0.76 0.32 1.79 0.83 0.42 1.63 0.20 0.12 0.33 
Income                                     
  <25,000 REF - - REF - - REF - - REF - - REF - - REF - - 
  25,000-49,999 0.90 0.62 1.31 0.74 0.44 1.25 0.47 0.28 0.79 0.70 0.50 0.98 0.79 0.54 1.15 0.36 0.26 0.50 
  50,000-74,999 0.76 0.46 1.27 0.69 0.38 1.27 0.34 0.19 0.62 0.61 0.36 1.04 0.49 0.35 0.68 0.21 0.15 0.31 
  75,000+ 1.20 0.77 1.86 0.47 0.25 0.87 0.19 0.11 0.34 0.71 0.48 1.04 0.45 0.31 0.66 0.15 0.10 0.22 
Marital Status                                     
  Married 0.18 0.08 0.39 0.18 0.09 0.35 0.03 0.01 0.08 0.43 0.27 0.67 0.29 0.19 0.45 0.16 0.10 0.25 
  Not Married REF - - REF - - REF - - REF - - REF - - REF - - 
Health Insurance                           
  Yes 1.02 0.68 1.52 0.67 0.45 1.00 0.37 0.24 0.59 0.58 0.42 0.82 0.51 0.38 0.68 0.27 0.20 0.36 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
                                          
    Significant Odds Ratio at the α=0.05 level 
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Table 5. Adjusted ORs and 95% Cls for Heroin Initiation in Past 12 Months and Heroin Use in Past 12 Months  Independent Variables Stratified by Non-Medical Pain Reliever (NMPR) User Type  
Variable 










No NMPR Use 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Year                                     
  2005 REF - - REF - - REF - - REF - - REF - - REF - - 
  2006 0.72 0.34 1.53 1.51 0.61 3.77 1.03 0.43 2.48 1.24 0.59 2.59 1.74 0.72 4.22 1.30 0.62 2.72 
  2007 0.95 0.45 2.01 1.70 0.69 4.18 0.45 0.18 1.14 1.31 0.66 2.58 1.35 0.66 2.79 0.41 0.19 0.91 
  2008 0.77 0.39 1.52 0.66 0.26 1.66 1.92 0.72 5.12 1.24 0.71 2.19 2.04 0.93 4.49 1.57 0.74 3.34 
  2009 1.02 0.54 1.92 2.63 1.06 6.52 1.24 0.44 3.46 1.59 0.87 2.90 2.42 1.26 4.65 1.75 0.86 3.58 
  2010 1.34 0.78 2.31 3.31 0.97 11.34 0.60 0.21 1.66 2.06 1.16 3.68 2.21 1.30 3.74 1.84 0.81 4.16 
  2011 1.43 0.65 3.17 2.75 1.14 6.67 1.23 0.44 3.46 2.86 1.52 5.39 2.62 1.35 5.06 2.05 0.98 4.27 
  2012 1.42 0.71 2.87 2.03 0.84 4.91 0.56 0.22 1.39 2.23 1.26 3.96 1.98 1.03 3.78 1.77 0.91 3.47 
  2013 2.29 1.07 4.92 2.72 1.11 6.66 0.78 0.35 1.73 2.52 1.40 4.52 2.60 1.56 4.32 1.17 0.64 2.13 
  2014 1.06 0.50 2.25 7.48 3.42 16.38 1.66 0.70 3.92 3.03 1.65 5.57 5.80 3.19 10.52 3.09 1.60 5.95 
Heavy Alcohol Use Past 12 M                                     
  Yes 0.64 0.46 0.89 0.78 0.50 1.22 0.77 0.41 1.45 0.64 0.46 0.88 0.69 0.47 0.99 0.63 0.40 0.99 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
Marijuana Use Past 12 Months                             
  Yes 1.45 0.81 2.59 4.78 2.60 8.80 9.28 4.43 19.46 2.18 1.36 3.49 1.59 1.01 2.49 2.75 1.59 4.76 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
Cocaine Use Past 12 Months                                     
  Yes 3.82 2.59 5.62 3.12 2.08 4.67 7.69 4.05 14.49 4.99 3.57 7.14 6.76 4.59 10.00 16.67 9.90 27.78 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
Injection Drug Use Ever                                     
  Yes 2.65 1.75 4.01 6.73 3.83 11.83 17.04 9.36 31.00 12.39 9.08 16.91 23.85 17.63 32.24 35.70 23.77 53.62 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
                                          
    Significant Odds Ratio at the α=0.05 level 
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Table 5 Continued. Adjusted ORs and 95% Cls for Heroin Initiation in Past 12 Months and Heroin Use in Past 12 Months  Independent Variables Stratified by Non-Medical Pain Reliever (NMPR) 
User Type  
Variable 










No NMPR Use 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Race/Ethnicity                                     
  White Non-Hispanic REF - - REF - - REF - - REF - - REF - - REF - - 
  Black Non-Hispanic 0.26 0.06 1.12 0.70 0.25 1.95 0.09 0.03 0.30 1.19 0.49 2.89 2.10 1.26 3.50 2.11 1.39 3.21 
  Hispanic 0.56 0.32 0.98 0.69 0.39 1.22 0.85 0.44 1.65 1.00 0.56 1.80 1.58 1.00 2.48 1.46 0.91 2.35 
  All Other 1.03 0.52 2.05 0.85 0.37 1.93 0.66 0.27 1.61 0.68 0.32 1.43 0.67 0.31 1.47 0.97 0.51 1.84 
Sex                                     
  Male 1.07 0.77 1.50 1.13 0.74 1.73 1.61 0.99 2.60 1.65 1.24 2.20 1.43 1.03 1.97 1.21 0.81 1.79 
  Female REF - - REF - - REF - - REF - - REF - - REF - - 
Age                                     
  12-17 0.88 0.64 1.21 1.09 0.70 1.71 1.32 0.84 2.10 0.60 0.43 0.84 0.72 0.48 1.07 0.83 0.58 1.19 
  18-25 REF - - REF - - REF - - REF - - REF - - REF - - 
  26-34 0.84 0.53 1.34 0.63 0.35 1.14 0.43 0.16 1.14 1.01 0.69 1.46 1.26 0.86 1.85 1.03 0.69 1.56 
  35-49 0.32 0.12 0.82 0.49 0.23 1.07 0.50 0.22 1.13 0.68 0.40 1.14 0.69 0.43 1.10 0.77 0.49 1.22 
  50+ 0.06 0.01 0.46 0.38 0.06 2.25 0.10 0.02 0.54 0.64 0.30 1.36 0.76 0.36 1.60 0.42 0.20 0.88 
Income                                     
  <25,000 REF - - REF - - REF - - REF - - REF - - REF - - 
  25,000-49,999 1.08 0.71 1.65 0.92 0.52 1.64 0.78 0.46 1.32 0.92 0.62 1.36 0.95 0.60 1.49 0.65 0.46 0.93 
  50,000-74,999 0.88 0.52 1.48 1.04 0.51 2.11 0.71 0.38 1.31 1.02 0.62 1.69 0.84 0.53 1.32 0.53 0.35 0.81 
  75,000+ 1.47 0.94 2.29 0.70 0.35 1.37 0.41 0.22 0.76 1.28 0.83 1.99 0.94 0.58 1.52 0.46 0.30 0.70 
Marital Status                             
  Married 0.32 0.13 0.77 0.43 0.19 0.97 0.13 0.05 0.36 0.48 0.28 0.85 0.46 0.28 0.77 0.42 0.24 0.75 
  Not Married REF - - REF - - REF - - REF - - REF - - REF - - 
Health Insurance                                     
  Yes 1.27 0.84 1.90 0.93 0.61 1.40 0.93 0.54 1.59 0.90 0.64 1.26 0.84 0.58 1.22 0.70 0.50 0.99 
  No REF - - REF - - REF - - REF - - REF - - REF - - 
                                          
    Significant Odds Ratio at the α=0.05 level 
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Figure 1: Percentage of past 12 month non-medical prescription opioid 
users reporting race/ethinicty as category other than 'white non-
Hispanic'
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Figure 2: Percentage of past 12 month non-medical prescription 
opioid users by age category 
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Figure 3: Frequency of non-medical prescription opioid use

















2005-2006 2007-2008 2009-2010 2011-2012 2013-2014
Figure 4: Percentage of past 12 month non-medical prescription opioid 
users using OxyContin in the past 12 months
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Figure 5: Percentage of past 12 month non-medical prescription opioid 














2005-2006 2007-2008 2009-2010 2011-2012 2013-2014
Figure 6: Percentage of past 12 month non-medical prescription opioid 
users using cocaine in past 12 months
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Figure 7: Percentage of past 12 month non-medical  prescription opioid 
users reporting ever injecting drugs
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APPENDIX A: ACRONYM GUIDE 
 
ACA  Affordable Care Act 
CI  Confidence Interval 
DEA  U.S. Drug Enforcement Agency 
ER  Extended-Release 
ER-OC Extended-Release OxyContin 
ICPSR  Inter-university Consortium for Political and Social Research 
KASPER Kentucky All Schedule Prescription Electronic Reporting System 
NASPER National All Schedule Prescription Electronic Reporting Act of 2005 
NMPR  Non-Medical Pain Reliever 
NMPR-N Non-Medical Pain Reliever Users Not Using OxyContin in Past 12 Months 
NMPR-O Non-Medical Pain Reliever Users Using OxyContin in Past 12 Months 
NMPR-X Non-Users of Non-Medical Pain Relievers in Past 12 Months 
NSDUH National Survey on Drug Use and Health 
OMB  Office of Management and Budget 
OR  Odds Ratio 
PDMP  Prescription Drug Monitoring Program 
RADARS Researched, Abuse, Diversion and Addiction-Related Surveillance 
SAMHSA Substance Abuse and Mental Health Services Administration 
SE  Standard Error 
TEDS  Treatment Episode Data Set 
